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ABSTRACT 
 
Eboneé Nicole Butler: Smoking and Variation in Breast Tumor Biomarker Expression 
(Under the direction of Melissa A. Troester) 
 
 
Purpose: Smoking is a suspected risk factor for breast cancer, with hypothesized 
links to estrogen-mediated, genotoxic, and growth-factor dependent mechanisms. Each 
mechanism can be modeled by overexpression of ER, p53, and EGFR, respectively. This 
dissertation examines associations between smoking and biomarkers for each mechanistic 
pathway. Methods: Our population-based study included 1,970 women diagnosed with 
invasive breast cancer in central and eastern North Carolina. Single and multigene biomarker 
outcomes were characterized as binary (+/-) or continuous measures for protein or mRNA. 
Single gene measures included ER/ESR1, p53/MDM2, and EGFR. Multigene mRNA 
signatures included a luminal score (LS); a p53 signature used to describe wild-type (Wt) or 
mutant (Mut) activity; and an algorithm-based proliferation score (PS). We used logistic and 
linear regression models to estimate associations between smoking and biomarker outcomes. 
Results: (Aim 1) When compared with never smokers, the odds of ER+, ESR1+, and LS+ 
tumors were nearly doubled among current smokers, those who smoked 20 or more years, 
and those who smoked within 5 years of diagnosis. Quantitative levels of ESR1 mRNA were 
highest among current smokers compared to never smokers overall and among women with 
ER+ breast cancer; however, we did not observe associations between smoking and 
continuous ER protein expression. (Aim 2) ER- cases with a history of ever smoking were at 
increased odds of having breast tumors with the p53 IHC+ molecular
iv 
phenotype. In addition, long smoking duration was also associated with higher quantitative 
levels of p53 protein among ER- breast tumors but not ER+ breast tumors. The EGFR IHC+ 
phenotype was inconsistently linked to smoking for both ER+ and ER- tumors. With respect 
to our multigene mRNA signatures, smoking was not linked to either the p53 Wt or p53 Mut 
subtype; however, with respect to the proliferation score, smoking metrics were consistently 
linked to lower odds for the PS+ subtype. Conclusions: Both single and multigene measures 
for each mechanistic pathway captured tumor changes associated with smoking. Findings 
from our study have implications for understanding potential mechanisms underlying 
smoking and breast cancer risk.  
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CHAPTER 1: SPECIFIC AIMS 
Smoking is a suspected risk factor for breast cancer, based on weak-to-moderate 
measures of association, and the detection of tobacco smoke particulates in breast tissues of 
smokers. However, the US Surgeon General concludes that there is insufficient evidence to 
suggest a causal relationship between active smoking and breast cancer risk. Indeed, 
epidemiologic studies have yielded mixed results. Because many breast cancers are estrogen 
dependent, studies that report earlier menopause and lower levels of circulating estrogens 
among smokers support an “anti-estrogenic” effect, and would suggest inverse risk. 
However, few epidemiologic studies have supported an “anti-estrogenic” hypothesis; studies 
have more commonly suggested a positive association between smoking and breast cancer 
risk, consistent with tissue culture and animal experiments, showing that cigarette smoke 
causes DNA-damage, disrupts cell-cycle regulation, and is linked to malignant 
transformation.  
Adding complexity to studies of smoking and breast cancer risk is the observation 
that breast cancer is a heterogeneous disease defined by distinct and reproducible gene 
expression profiles. These gene expression profiles reflect breast cancer “intrinsic subtypes” 
that are prognostic and predictive of response to treatment, and also appear to have distinct 
etiologic profiles. However, the relationship between smoking and breast cancer intrinsic 
subtype has not been completely evaluated. Furthermore, proposed mechanisms of the 
smoking-breast cancer relationship have implicated at least three mechanistic pathways: 
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estrogen-mediated, genotoxic, and growth factor-mediated. Thus, a critical examination of 
smoking and breast cancer risk would benefit by examining intrinsic subtype and tumor 
biomarkers linked to pathogenesis. Moreover, such studies should carefully incorporate 
information on dose and timing of exposure. The examination of temporal and dose-
dependent patterns of smoking in relation to biomarker-defined breast cancer subtypes may 
identify time-windows of susceptibility that are associated with specific breast cancer 
subtypes.  
The current proposal uses data from the population-based Carolina Breast Cancer 
Study (CBCS), which combines molecular biology and epidemiology to examine genetic and 
environmental risk factors for breast cancer. The CBCS has collected protein and RNA 
expression data on genes involved in breast tumor biology, specifically: estrogen receptor 
(ER) protein and RNA expression; p53 protein and p53-dependent RNA expression; and 
epidermal growth factor receptor (EGFR) protein and RNA expression. These hypotheses 
will be evaluated while simultaneously considering breast cancer intrinsic subtype.  
Aim 1: To examine the relationships between temporal and dose-dependent patterns 
of smoking, breast cancer intrinsic subtype, and ER expression. Rationale: Growing evidence 
suggests a possible association between smoking and the luminal, estrogen receptor (ER)-
positive breast cancer subtypes, ranging from a modest 5% increased risk to more than 
doubled risk when comparing ever smokers with never-smokers. Hypothesis: Smoking will 
be quantitatively and qualitatively associated with increased risk of luminal/ER+ breast 
cancer and inverse risk of basal-like/ER- breast cancer. Approach: To examine the temporal 
and dose-dependent relationship between smoking and continuous and categorical measures 
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of i) luminal and basal-like intrinsic subtypes and; ii) ER protein expression and ESR1 RNA 
levels.  
Aim 2a: To examine the relationships between temporal and dose-dependent patterns 
smoking, breast cancer intrinsic subtype, and p53 expression. Rationale: Studies have 
reported that breast cancer patients who were self-reported smokers at time of diagnosis had 
higher prevalence of specific TP53 mutations compared to their non-smoking counterparts. 
P53 expression regulates genomic stability and the DNA-damage response and may be an 
important mechanism underlying the relationship between smoking and breast cancer risk. 
Hypothesis: Temporal and dose-dependent variation in smoking is associated with variations 
in risk of p53 mutant cancers. Approach: To evaluate the temporal and dose-dependent 
association between smoking and p53+ breast cancer risk as measured by IHC and p53-
dependent RNA signature.  
Aim 2b: To examine the relationships between temporal and dose-dependent patterns 
of smoking, breast cancer intrinsic subtype, and EGFR expression: Rationale: In vitro studies 
of breast epithelial cells treated with nicotine have demonstrated higher expression of EGFR 
compared to untreated cells, providing evidence for nicotine as a possible environmental 
agent linked to EGFR+ breast cancer. Hypothesis: Temporal and dose-dependent variation in 
smoking exposure is associated with variations in EGFR+ breast cancer risk. Approach: To 
evaluate the temporal and dose-dependent association between smoking and EGFR+ breast 
cancer risk as measured by IHC and RNA expression. 
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CHAPTER 2: BACKGROUND 
This year nearly 250,000 US women will be diagnosed with breast cancer1. Of these 
cases, only 1 in 4 will be attributed to high-penetrance germline mutations or familial clusters 
of the disease. The remaining three-fourths will have no known markers of heritable 
susceptibility, leaving patients, communities, and researchers to grapple with understanding 
how environments and individual behaviors influence breast cancer risk. The identification of 
breast cancer intrinsic subtypes adds to the difficult task of understanding breast cancer 
etiology, as each subtype is hypothesized to have a distinct risk factor profile. It follows that 
a critical evaluation of any risk factor must consider the inherent heterogeneity across breast 
tumors, including differential expression of biomarkers linked to pathogenesis. Smoking is a 
suspected cause of breast cancer and has been linked to breast tumors that arise via estrogen-
mediated, genotoxic, and growth-factor dependent mechanisms. In this proposal, we will 
examine the association between smoking exposure and breast tumor expression of 
biomarkers that reflect biologic activity of each mechanistic pathway. We will also examine 
temporal and dose-dependent patterns of smoking to identify etiologically-relevant time 
windows that may be associated with early or late carcinogenic events in the development of 
biomarker-defined breast tumors. By examining smoking exposure in relation to biomarkers 
linked to pathogenesis, we may identify etiologically-relevant subtypes that have been 
masked in prior studies of smoking and breast cancer risk.
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2.1  Two Etiologic Types of Breast Cancer 
The heterogeneous nature of breast cancer has been well-established with the 
identification of distinct and reproducible intrinsic subtypes2. Gene expression studies have 
identified at least four subtypes that occur with predictable frequencies in representative 
populations of US women3-5, namely: Luminal A, Luminal B, HER2-enriched (HER2E), and 
basal-like breast tumors. Luminal A tumors are most common, occurring in approximately 
seventy percent of cases. In comparison to other subtypes, Luminal A tumors are the most 
genetically diverse and are characterized by high estrogen signaling, respond to hormone 
therapy, and may carry the most favorable prognoses6. Luminal B and HER2E tumors 
account for approximately ten and five percent of breast cancer cases, respectively. These 
two subtypes are characterized by overexpression or amplification of HER2 and may respond 
to hormone therapy and the monoclonal antibody, trastuzumab. However, Luminal B tumors 
have higher levels of estrogen signaling when compared with HER2E tumors. Estimates for 
the prevalence of basal-like tumors range between 10 and 20 percent of breast cancer cases. 
Basal-like tumors are characterized by low estrogen-signaling, lack targeted therapies, and 
are associated with clinical markers for aggressive disease. Though Luminal A, Luminal B, 
and HER2E tumors are defined by distinct gene expression profiles, each expresses proteins 
that are found predominantly in the luminal epithelial layer of the mammary gland and are 
thought to share luminal epithelial origins. By contrast, tumors that are classified as basal-
like express proteins that are most abundant in the basal/myoepithelial layer of the mammary 
gland.  
Though intrinsic subtypes have both predictive and prognostic value, less is known 
concerning their utility in studies of etiology. Breast cancer incidence trends have been used 
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to suggest the existence of two main etiologic types – luminal and basal-like – based on 
estrogen-receptor expression and average age at onset7,8. Basal-like breast cancers are 
estrogen-receptor negative (ER-) and have a younger average age at onset relative to luminal 
breast cancers, which are estrogen-receptor positive. This observation supports arguments 
that breast cancers of luminal epithelial and basal/myoepithelial origins represent two distinct 
etiologic classes of disease. In addition, a growing number of genomic platforms have 
identified two distinct breast cancer clusters when representative samples of breast tumors 
are compared with tissues from other cancer types9. These clusters are characterized by 
tumors that are ER+ and ER-, which map to the luminal and basal-like phenotypes, 
respectively. 
Several epidemiologic studies have examined associations between traditional breast 
cancer risk factors and breast tumors stratified by ER status (i.e., ER+ vs. ER-) or luminal 
and basal-like designations. Early age at menarche, African American race, and young age 
are associated with increased risks of Basal-like or triple-negative breast cancers10-13; these 
non-modifiable risk factors may reflect unmeasured risk factor profiles that increase 
susceptibility to the basal-like phenotype. Lower body mass index (BMI) and breastfeeding 
among women with high parity are two modifiable risk factors associated with inverse risk of 
the basal-like breast cancer type10,12-16. Alcohol intake has been consistently linked to 
increased risk of breast cancer, with many studies showing evidence of a strong association 
with luminal or estrogen-receptor positive disease15,17. Further, risks for luminal and basal-
like breast cancers may differ by physical activity engagement, first degree family history of 
breast cancer16, menopausal status18, income, exposure to exogenous hormones10, and age at 
first pregnancy19,20.  
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2.2 Smoking and Breast Cancer Risk  
Although the prevalence of cigarette smoking has steadily decreased since the 1950s, 
approximately 50% of women in the United States report a history of ever smoking and 14% 
are self-reported current smokers21. The Surgeon General’s 2014 report on the “health 
consequences of smoking” suggests there is sufficient evidence to identify mechanisms by 
which cigarette smoke could cause breast cancer, based on data from animal studies; the 
report concludes, however, that current population-based evidence is insufficient to infer 
causation. This conclusion has been attributed to inconsistent results from epidemiologic 
investigations, including the lack of an observed dose-response relationship. Indeed, 
epidemiologic studies of smoking and breast cancer risk have yielded a mix of positive and 
null findings, suggesting little or no increased risk of disease. And as in most studies of 
smoking and cancer incidence, duration – but not dose – has been more consistently 
associated with risk.   
Several contemporary studies of smoking and breast cancer risk have reported 
positive associations in both age- and ethnically-diverse populations of women (Table 2.1). 
Investigators from the Multiethnic Cohort Study, Cancer Prevention Study II, Black 
Women’s Health Study, and Nurse’s Health Study have demonstrated positive, though 
modest, associations for smoking status (i.e., current, former, never), dose, and duration and 
breast cancer risk. In a meta-analysis of 15 cohort studies, Gaudet et al. estimated a 10 
percent increased risk of breast cancer among women who were current smokers at time of 
study enrollment (HR 1.1, 95% CI = 1.1 to 1.2) and a 10 percent increased risk among 
women who were classified as former smokers (HR 1.1, 95% CI = 1.0 to 1.2), when 
compared with never smokers. These large-scale cohort studies improve upon prior 
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investigations by addressing biases inherent to observational study designs, including 
minimizing the potential for recall bias and control for confounding or effect measure 
modification due to established breast cancer risk factors. However, few studies have 
considered the heterogeneous nature of breast cancer as a source of bias in etiologic 
investigations and its potential to mask associations between smoking and distinct molecular 
subtypes of breast cancer. 
2.3 Smoking and Breast Tumor Biomarkers Linked to Pathogenesis 
Tobacco smoke includes more than 70 carcinogens that have been evaluated by the 
International Agency for Research on Cancer (IARC), and which comprise eight chemical 
classes 20. Two of the largest classes – the polycyclic aromatic hydrocarbons (PAHs) and the 
N-nitrosamines – are thought to be responsible for cancer initiation in lung tumors. 
Moreover, PAHs, N-nitrosamines – and their predecessor, nicotine – have been examined in 
human breast tissue and tissue culture for their ability to transform normal breast epithelium 
to cancer22-24. Metabolized forms of PAHs and the tobacco-specific N-nitrosamines can form 
covalent bonds at susceptible nucleotide binding sites to form DNA-adducts21. If the affected 
cell evades an arsenal of DNA repair mechanisms (e.g., nucleotide excision repair), the 
resultant adduct can yield single-base point mutations that may render a gene’s protein 
product non-functional. Further, smoking exposure may also result in chromosomal breaks 
and loss of heterozygosity, leading to DNA copy number aberration. Thus, protein and RNA 
expression levels of key genes may provide clues to understanding the etiology of smoking 
and breast cancer risk.  
Smoking has been linked to breast tumors that arise via estrogen-mediated, genotoxic, 
and growth-factor dependent mechanisms; these mechanisms can be modeled by 
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overexpression of the estrogen-receptor, TP53, and epidermal growth factor receptor (ER, 
p53, and EGFR), respectively. The overexpression of each marker reflects aberrant changes 
in cell-cycle regulation and homeostatic disruption of the tumor microenvironment, which 
allow a single cancer cell to gain selective advance and multiply through clonal expansion. 
By examining smoking exposure in relation to biomarkers linked to pathogenesis, we may 
identify etiologically-relevant subtypes that have been masked in prior epidemiologic studies 
of smoking and breast cancer risk.  
2.3.1 Intrinsic Subtype  
Triple subtypes – defined as the joint expression of the estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) – have 
been used as surrogates for intrinsic subtype in studies of breast cancer etiology. Each marker 
is measured by IHC or mRNA assay and is designated as positive (+) or negative (-), based 
on clinicopathologic cut points for overexpression. Luminal types are typically defined as 
tumors that are ER+ and or PR+, irrespective of HER2 expression. And triple negative 
tumors, surrogates for Basal-like tumors, are negative for all three markers. Although triple 
subtypes strongly correlate with gene expression profiles for intrinsic subtype, varying levels 
of discordance exist25. For example, approximately 75% of triple negative tumors are 
confirmed as Basal-like by gene expression assay, while the remaining 25% can be 
genetically similar to Luminal breast cancers. Thus, triple subtype designations are a 
potential source of outcome misclassification and may yield inconsistent results across 
studies of smoking and subtype-specific breast cancer risk. Smoking exposure has been 
variably linked to increased risk of the Luminal subtype and has more consistently showed a 
null association with the Basal-like subtype (Table 2.2). As shown in the Carolina Breast 
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Cancer Study, triple subtypes can be further refined by IHC assessment of cytokeratin 5/6 
(CK 5/6) and epidermal growth factor receptor (EGFR), which are characteristic of the 
Basal-like phenotype. Future studies of smoking and breast cancer risk can also benefit from 
gene expression profiling of tumors, as described by the PAM50 gene signature. 
2.3.2 Estrogen Receptor 
With a large majority of breast cancers driven by exposure to estrogen, it has been 
suggested that the anti-estrogenic properties of cigarette smoke counteract its carcinogenic 
effects, leading to null or inconsistent associations of smoking and breast cancer risk among 
smokers26. This hypothesis is supported by the observation that smokers report earlier age at 
menopause and have lower levels of circulating estrogens. Nevertheless, epidemiologic 
investigations have commonly demonstrated a positive association between smoking and 
breast cancer risk, particularly for ER+ tumors (Table 2.3). In a recent population-based case-
control study of women in the Seattle Puget-Sound metropolitan area, Kawai et al. reported a 
40% increased risk of ER+ breast cancer among ever smokers (OR 1.4, 95% CI = 1.0 to 1.9), 
but found no association between smoking and ER- tumors. Similarly, in the Cancer 
Prevention Study II, Gaudet et al. reported a 20% increased risk of ER+ breast cancer among 
current smokers (OR 1.2, 95% CI = 1.0 to 1.5) and a 10% increased risk of ER+ breast 
cancer among former smokers (OR 1.1, 95% CI = 1.1 to 1.3); results among women in the 
AARP cohort show a 40% increased risk of ER+ breast cancer among current smokers (HR 
1.4, 95% CI = 1.0 to 1.8). Neither of these studies reported associations between smoking 
and estrogen-receptor negative (ER-) breast cancer, suggesting that smoking exposure may 
be related distinct pathophysiologic pathways leading to overexpression of the estrogen 
receptor. However, in stark contrast to contemporary studies in North American populations, 
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older studies of smoking and breast cancer risk in Swedish and Swiss populations have 
demonstrated positive associations between smoking and ER- breast cancer. Thus, a careful 
investigation should consider era and characteristics of population of interest. 
2.3.3 Tumor protein p53  
TP53 (or p53) is the most frequently mutated gene in breast cancer with estimates 
ranging between 20 to 40 percent of all cases. Investigators have demonstrated that breast 
cancer patients who are self-reported smokers at time of diagnosis have a higher prevalence 
of specific TP53 mutations when compared with their non-smoking counterparts. In the 
absence of gene sequence technologies, epidemiologists have employed IHC staining as one 
high throughput method to detect p53 protein expression in breast tumors. Nuclear staining 
of p53 positively correlates with TP53 missense mutations, which render non-functional 
forms of the protein. In a case-case analysis, Gammon et al. reported that smokers were twice 
as likely to be diagnosed with p53+ breast cancer when compared to never smokers, where 
p53-positivity was defined as moderate to strong staining in 10% or greater of tumor cells 
(Table 2.4). Furberg et al. suggest that the relationship between smoking and p53+ breast 
cancer risk may be null; here, the authors defined p53-positivity as dark nuclear staining in 
10% or greater of examined tumor cells. The discordant results between the two studies may 
be explained by differences in protocol and the selection of the p53 IHC cut point. Given the 
evidence that breast cancer patients who are smokers harbor a greater proportion of TP53 
mutations, and that p53 protein IHC expression correlates with TP53 missense mutation, it is 
plausible that the threshold selected by Furberg et al. did not accurately categorize tumors 
with and without TP53 missense mutations, thereby yielding a spurious null association 
between smoking and p53 expression in breast tumors.  
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2.3.4 Epidermal Growth Factor Receptor 
Until recently, nicotine - the most abundant and pharmacologically active component 
of cigarette smoke – had not been implicated in the development of breast cancer. Mouse 
xenograft models have shown that normal mammary cells transform to neoplastic cells upon 
exposure to nicotine and its derivatives27. And similar to findings from lung cancer studies28, 
breast epithelial cells treated with nicotine show increased rates of cell proliferation through 
activation of EGFR29, providing a measurable biological endpoint for a hypothesized 
association between nicotine and EGFR+ breast cancer risk. EGFR overexpression is present 
in nearly three-fourths of basal like breast tumors, predicting increased risk of recurrence and 
poorer overall survival. Although less common, EGFR-positivity is also observed among 
Luminal A, Luminal B, and human epidermal growth factor receptor-2 (HER2) enriched 
intrinsic subtypes to varying degrees; however, its prognostic value for these breast tumor 
subtypes has not been defined. A recent study of basal-like marker expression (i.e., EGFR 
and/or CK 5/6) in luminal tumors showed that the distribution of traditional breast cancer risk 
factors (i.e., family history of breast cancer, age at menarche, parity, age at first full-term 
pregnancy, number of live births, breast feeding, and BMI) did not differ according to EGFR 
expression30. Although there were no apparent etiologic differences, Luminal tumors that 
expressed EGFR had more favorable clinical features when compared with tumors that did 
not express EGFR.  
At present, no studies have examined the epidemiology of EGFR+ breast cancer. 
Several studies, however, have examined tumor and clinical characteristics with respect to 
EGFR expression using IHC cut points of 1% or 10% of stained tumor cells to characterize 
tumors as positive or negative. Tumors defined as EGFR+ were less likely to express ER or 
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PR and were positively correlated with chromosome 7 polysomy, HER2 gene amplification, 
and EGFR protein expression31-35. EGFR+ tumors have also been shown to have inverse 
associations with disease-free survival, are more likely to have positive associations with 
lymph node status, and may be associated with specialized histological breast cancer types. 
In addition, EGFR+ tumors may be associated with higher proliferative fractions, increased 
aneuploidy, and increased tumor size. Although there is little data regarding the 
epidemiology of EGFR+ disease, investigators for study of early stage breast cancer patients 
reported positive associations between high EGFR tumor expression, African American race, 
and young age.  
The proposed study will be the first to investigate the association between smoking, 
concomitant nicotine exposure, and risk of breast cancer characterized by overexpression of 
EGFR. It is important to emphasize that prior investigations of smoking and breast cancer 
intrinsic subtype found no link between smoking and basal-like breast cancer, of which 
nearly three-fourths overexpress EGFR36. Recall, however, that EGFR may be overexpressed 
for all intrinsic subtypes to varying degrees25,36,37. Thus, dichotomizing breast cancers by 
EGFR expression (i.e., EGFR+ and EGFR-) will allow us to specifically assess whether 
smoking is associated with EGFR+ breast cancer across subtypes. 
2.4 Exposure-Time-Windows and Breast Cancer Risk 
Prior investigations of smoking and breast cancer risk have typically used crude 
definitions of induction and latency periods for disease. Recall that induction and latency 
periods are defined as the time between exposure and disease initiation – and the time 
between disease initiation and disease manifestation, respectively. Cohort studies have most 
commonly used baseline measures of smoking, which may not reflect exposure levels at time 
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of breast cancer diagnosis (Table 2.1). Both cohort and case-control studies have 
incorporated measures of smoking initiation with respect to categories of age and smoking 
cessation relative to time-windows preceding disease diagnosis. These exposure-time-
windows are defined by the investigator and observed associations may be sensitive to 
selected cut points. Improper specification of induction and latency periods leads to non-
differential exposure misclassification and biases effect estimates toward the null38. Thus, 
methods that allow researchers to examine temporal patterns of smoking without selecting 
time periods a priori may be beneficial in studies of smoking and breast cancer risk.  
The current proposal seeks to explore the temporal relationship between smoking and 
breast cancer risk. Logistic regression models that include parametric latency functions can 
be used to evaluate variation in disease risk by time since exposure. The inclusion of a 
parametric latency function in our logistic regression model will allow us to calculate time 
weighted exposure estimates using maximum likelihood estimation, where the highest 
weights are assigned during the period where smoking is associated with the greatest risk of 
EGFR positive breast cancer. In addition, non-parametric functions (e.g., B-splines) – which 
do not impose a specified probability distribution – can be used to visualize trends that 
describe differential breast cancer risk along the course of a woman’s smoking history. 
Further, as we explore temporal patterns of smoking in relation to biomarker-defined breast 
cancer types, we may observe associations that allow us to hypothesize temporal associations 
for the activation of a given mechanistic pathway with respect to smoking exposure. 
Specifically, evidence of an association between smoking and breast cancer risk proximal to 
time of diagnosis infers a late-acting carcinogenic event. By contrast, if smoking exposure is 
associated with breast cancer risk at a distal point from date of diagnosis, we may infer that 
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smoking is associated with an early carcinogenic event. By using latency models for 
protracted exposures, we will identify exposure time frames where smoking is most 
etiologically relevant to biomarker-defined breast tumors.  
2.5 Summary 
Identifying the component causes of breast cancer remains one of the greatest public 
health challenges of the 21st century. Researchers have proposed smoking as a probable risk 
factor the disease; however, a definitive relationship between smoking and breast cancer risk 
has not been established. In this proposal, we will consider the heterogeneous nature of breast 
cancer and its potential to mask associations between smoking and distinct molecular 
subtypes of breast cancer. We will also examine temporal patterns of smoking exposure 
using data-driven approaches that incorporate maximum likelihood estimation to identify 
critical exposure-time-windows. Results from our study may help to elucidate associations 
masked in prior studies.  
2.6 Literature Review Tables 
See next page.
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Table 2.1. Temporal and dose-dependent measures of smoking and breast cancer risk. 
Reference Study Design and 
Overview 
Temporal 
relative to date  
of study enrollment 
Duration 
 (years) 
Dose 
 (cigarettes/day) 
Catsburg 
(2014)39 
Case-cohort. The Canadian 
Study of Diet, Lifestyle and 
Health (CSDLH). There 
were 1,096 breast cancer 
cases and 3,314 women 
included in the sub-cohort 
(approximately 4% of those 
in sub-cohort became 
cases). Smoking exposure 
was determined by self-
administered questionnaire. 
The authors observed no 
apparent association 
between smoking measures 
and breast cancer risk. 
Current vs. 
Never 
 
Former vs. 
Never 
 
HR (95% CI) 
1.0 (0.8 to 1.4) 
 
HR (95% CI) 
1.0 (0.9 to 1.2) 
Overall 
<10 
10 - < 20 
20 - < 30 
30 - < 40 
40+ 
Never 
 
HR (95% CI) 
0.9 (0.8 to 1.2) 
1.2 (0.9 to 1.5) 
0.9 (0.7 to 1.2) 
1.2 (0.9 to 1.5) 
0.9 (0.6 to 1.3) 
(Ref) 
 
Overall 
20+ 
15 - < 20 
10 - < 15 
5 - < 10 
< 5 
Never 
 
HR (95% CI) 
1.0 (0.7 to 1.3) 
1.1 (0.8 to 1.4) 
1.1 (0.9 to 1.5) 
1.0 (0.8 to 1.3) 
0.9 (0.7 to 1.1) 
(Ref) 
 
Cui  
(2006)40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cohort. Canadian National 
Breast Screening Study 
(NBSS). Approximately 
90,000 women were 
recruited for a randomized 
controlled trial of 
mammographic screening 
for breast cancer; 4,445 
became cases. Women were 
followed for an average of 
16 years. Smoking exposure 
was assessed at baseline. 
Long smoking duration 
(>40 years), smoking dose 
(40+ cigarettes/day), and 
smoking initiation 40 years 
prior to study enrollment 
Smoking Start 
Years Prior 
1-9 
10-19 
20-29 
30-39 
40+ 
Never 
 
RR (95% CI) 
1.0 (0.8 to 1.3) 
1.1 (0.9 to 1.2) 
1.0 (1.0 to 1.1) 
1.1 (1.0 to 1.2) 
1.3 (1.1 to 1.6) 
(Ref) 
 
 
 
 
 
 
 
 
 
Overall 
1-9 
10-19 
20-29 
30-39 
40+ 
Never 
 
HR (95% CI) 
1.0 (0.9 to 1.1) 
1.0 (0.9 to 1.1) 
1.1 (1.0 to 1.2) 
1.1 (1.0 to 1.3) 
1.5 (1.2 to 1.9) 
(Ref) 
 
Overall 
1-9 
10-19 
20-29 
30-39 
40+ 
Never 
RR (95% CI) 
1.0 (0.9 to 1.1) 
1.1 (1.0 to 1.2) 
1.1 (1.0 to 1.2) 
1.1 (0.9 to 1.3) 
1.2 (1.0 to 1.4) 
(Ref) 
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Reference Study Design and 
Overview 
Temporal 
relative to date  
of study enrollment 
Duration 
 (years) 
Dose 
 (cigarettes/day) 
(continued) 
 
 
was associated with 
increased breast cancer risk. 
Dossus 
(2014)41 
Cohort. European 
Prospective Investigation 
into Cancer. Of the 322,988 
women enrolled in the 
study, 9,822 developed 
breast cancer over an 
average follow-up period of 
11 years. Smoking was 
assessed by baseline 
questionnaire. The authors 
observed a slight association 
between current or former 
smoking and increased 
breast cancer risk. There 
was a trend between 
increasing smoking duration 
and increased risk among 
current smokers. This trend 
was not evident among 
former smokers although 
the highest categories of 
smoking duration were 
associated with increased 
risk for this group. The 
highest categories of 
smoking dose were also 
associated with increased 
breast cancer risk for current 
and former smokers. 
Current vs. 
Never 
 
Former vs. 
Never 
 
HR (95% CI) 
1.1 (1.0 to 1.1) 
 
HR (95% CI) 
1.1 (1.0 to 1.1) 
Current 
Smokers 
0-10 
10-20 
20-30 
>30 
Never 
 
Former 
Smokers 
0-10 
10-20 
20-30 
>30 
Never 
 
HR (95% CI) 
0.9 (0.7 to 1.3) 
1.0 (0.8 to 1.1) 
1.0 (1.0 to 1.1) 
1.1 (1.0 to 1.2) 
(Ref) 
 
 
HR (95% CI) 
1.1 (1.0 to 1.2) 
1.0 (0.9 to 1.1) 
1.1 (1.0 to 1.2) 
1.0 (0.9 to 1.1) 
(Ref) 
 
Current 
Smokers 
<6 
6-10 
10-15 
≥15 
Never 
 
Former 
Smokers 
<6 
6-10 
10-15 
≥15 
Never 
 
HR (95% CI) 
1.0 (0.9 to 1.1) 
1.0 (0.9 to 1.2) 
1.1 (1.0 to 1.2) 
1.1 (1.0 to 1.2) 
(Ref) 
 
 
HR (95% CI) 
0.9 (0.9 to 1.0) 
1.0 (0.9 to 1.1) 
1.1 (1.0 to 1.2) 
1.1 (1.0 to 1.3) 
(Ref) 
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Reference Study Design and 
Overview 
Temporal 
relative to date  
of study enrollment 
Duration 
 (years) 
Dose 
 (cigarettes/day) 
Gaudet 
(2013)42 
Cohort. The Cancer 
Prevention Study II (CPS-
II) Nutrition Cohort. 97,786 
women were enrolled in 
1992 to examine cancer 
incidence and mortality. 
Median follow-up was 14 
years 3,721 invasive breast 
cancers occurred. Both 
current and former smoking 
were associated with slight 
increased risks of breast 
cancer. Among former 
smokers, long duration (31 
to 70 years) was associated 
with breast cancer risk. 
However, duration was not 
associated with risk among 
current smokers. There was 
no apparent association 
between smoking dose and 
breast cancer risk. 
Current vs. 
Never 
 
Former vs. 
Never 
 
HR (95% CI) 
1.3 (1.1 to 1.4) 
 
HR (95% CI) 
1.1 (1.1 to 1.2) 
Current 
Smokers 
1-40 
40-49 
50-73 
Never 
 
Former 
Smokers 
<1-10 
11-20 
21-30 
31-70 
Never 
 
HR (95% CI) 
1.2 (0.9 to 1.5) 
1.0 (0.9 to 1.4) 
1.0 (0.9 to 1.6) 
(Ref) 
 
 
HR (95% CI) 
1.2 (1.1 to 1.3) 
1.2 (1.1 to 1.3) 
1.1 (1.1 to 1.3) 
1.0 (1.2 to 1.4) 
(Ref) 
 
Current 
Smokers 
1-9 
10-19 
20-29 
30-39 
40-90 
Never 
 
 
 
HR (95% CI) 
1.2 (0.9 to 1.7) 
1.0 (0.8 to 1.3) 
1.2 (1.0 to 1.5) 
1.1 (0.7 to 1.8) 
1.4 (0.8 to 2.4) 
(Ref) 
 
 
 
Gram 
(2015)43 
 
 
 
 
 
 
 
 
 
 
Cohort. The Multiethnic 
Cohort (MEC) Study. 
83,300 women were 
enrolled and followed 
between 1993 and 2010. Of 
these, 4,484 developed 
invasive breast cancer. 
Smoking was assessed at 
baseline via questionnaire. 
Both current and former 
smoking were associated 
with slight increased risk of 
Current vs. 
Never 
 
Former vs. 
Never 
 
HR (95% CI) 
1.1 (1.0 to 1.2) 
 
HR (95% CI) 
1.0 (1.0 to 1.1) 
Overall 
≤20 
21-30 
>30 
Never 
 
 
HR (95% CI) 
1.0 (0.9 to 1.1) 
1.2 (1.1 to 1.3) 
1.1 (1.0 to 1.2) 
(Ref) 
 
 
Overall 
≤10 
11-20 
>20 
Never 
 
 
HR (95% CI) 
1.0 (0.9 to 1.1) 
1.1 (1.0 to 1.2) 
1.2 (1.0 to 1.3) 
(Ref) 
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Reference Study Design and 
Overview 
Temporal 
relative to date  
of study enrollment 
Duration 
 (years) 
Dose 
 (cigarettes/day) 
(continued) 
 
breast cancer. Long 
smoking duration and high 
dose were also associated 
with increased risk of 
disease. 
Nyante  
(2014)44 
Cohort. AARP (formerly 
American Association of 
Retired Persons). 186,150 
female study participants 
were enrolled in 1995-96 
and followed for an average 
of 10 years. Smoking 
exposure was assessed via 
baseline questionnaire. 
However, smoking duration 
was not assessed at baseline. 
Current and former smoking 
were associated with slight 
increased risk of breast 
cancer. There was no 
apparent trend between 
smoking dose and breast 
cancer risk.  
Current vs. 
Never 
 
Former vs. 
Never 
 
HR (95% CI) 
1.2 (1.1 to 1.3) 
 
HR (95% CI) 
1.1 (1.0 to 1.1) 
Not reported.  Current 
Smokers 
1-10 
11-20 
21-30 
31-40 
≥41 
Never 
 
Former 
Smokers 
1-10 
11-20 
21-30 
31-40 
≥41 
Never 
 
 
 
HR (95% CI) 
1.2 (1.0 to 1.3) 
1.2 (1.1 to 1.4) 
1.1 (0.9 to 1.2) 
1.1 (0.9 to 1.4) 
1.4 (0.6 to 1.5) 
(Ref) 
 
 
HR (95% CI) 
1.1 (1.0 to 1.2) 
1.0 (1.0 to 1.1) 
1.2 (1.1 to 1.3) 
1.2 (1.1 to 1.4) 
1.1 (0.9 to 1.2) 
(Ref) 
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Reference Study Design and 
Overview 
Temporal 
relative to date  
of study enrollment 
Duration 
 (years) 
Dose 
 (cigarettes/day) 
Rosenberg 
(2013)45 
Cohort. The Black Women's 
Health Study. 52,425 
women were followed for 
14 years between 1997 and 
2009. 1,377 breast cancer 
cases occurred. Smoking 
was assessed at baseline via 
questionnaire. When 
compared with never active 
or passive smokers, current 
and former smoking were 
not associated with 
increased breast cancer risk. 
Women who smoked 20 
pack-years had slight 
increased risk of breast 
cancer. 
Current vs. 
Never Active 
or Passive 
 
Former vs. 
Never Active 
or Passive 
 
IRR (95% CI) 
1.1(0.8 to 1.3) 
 
 
IRR (95% CI) 
1.1 (0.9 to 1.4) 
Pack-years 
<10 
10-19 
20 
IRR (95% CI) 
1.1 (0.9 to 1.3) 
1.0 (0.8 to 1.3) 
1.2 (1.0 to 1.5) 
Reported composite measure of 
pack-years. 
Xue 
(2011)46 
Cohort. The Nurse's Health 
Study. 111,140 women were 
enrolled at baseline (1976) 
and were followed through 
2006. 8,772 incident cases 
of breast cancer occurred. 
Active smoking exposure 
was assessed via baseline 
questionnaire and updated 
biennially. Current and 
former smoking were 
associated with increased 
risk of breast cancer.  
Current vs. 
Never 
 
Former vs. 
Never 
 
HR (95% CI) 
1.1 (1.0 to 1.2) 
 
HR (95% CI) 
1.1 (1.0 to 1.1) 
Overall 
<20 
20-39 
≥40 
Never 
 
 
HR (95% CI) 
1.0 (1.0 to 1.1) 
1.1 (1.0 to 1.1) 
1.2 (1.0 to 1.3) 
(Ref) 
 
 
Current 
Smokers 
1-14 
15-24 
≥25 
Never 
 
Former 
Smokers 
1-14 
15-24 
≥25 
Never 
 
 
 
HR (95% CI) 
1.0 (0.9 to 1.2) 
1.1 (1.0 to 1.2) 
1.1 (1.0 to 1.3) 
(Ref) 
 
 
HR (95% CI) 
1.0 (1.0 to 1.1) 
1.1 (1.0 to 1.2) 
1.1 (1.0 to 1.2) 
(Ref) 
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Table 2.2. Associations between smoking and risk of breast cancer intrinsic subtype. 
Reference Study Design and 
Overview 
Molecular Platform 
and definition  
of positive subtype 
Smoking and Biomarker 
Contrast 
Measure of Effect 
Butler 
(2016)47 
Case-control. The Carolina 
Breast Cancer Study. Study 
enrollment included 1,803 
cases and 1,564 controls. 
Data on smoking exposure 
was obtained during a 
nurse-administered 
interview. Current smoking 
was associated with 
increased risk of Luminal 
breast cancer and slight 
decreased risk of Basal-like 
breast cancer. 
 
Medical 
Records and 
IHC Staining 
Luminal: 
ER+ and/or 
PR+, HER2- 
 
Basal-like: 
ER-, PR-, 
HER2-EGFR+ 
and/or CK 
5/6+ 
Current vs. 
Never 
 
Current vs. 
Never 
 
Luminal vs.  
Controls 
 
Basal-like vs.  
Controls 
OR and 95% CI  
1.5 (1.1 - 2.0) 
 
OR and 95% CI  
0.8 (0.5 - 1.5) 
 
Kabat 
(2011)48 
Cohort. The Women's 
Health Initiative (WHI). 
148,030 women aged 50-79 
were enrolled between 1993 
and 1998 and followed over 
an 8-year period. Smoking 
exposure was assessed at 
baseline via questionnaire. 
There was no apparent 
association between current 
or former smoking and 
TNBC risk. 
 
Medical 
Records and 
Pathology 
Reports 
TNBC: 
ER-/PR-
/HER2- 
 
 
 
Current vs. 
Never 
 
Former vs. 
Never 
 
TNBC vs.  
Non-cases 
 
TNBC vs.  
Non-cases 
HR and 95% CI  
1.1 (0.7 - 1.7) 
 
HR and 95% CI  
0.9 (0.7 - 1.2) 
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Reference Study Design and 
Overview 
Molecular Platform 
and definition  
of positive subtype 
Smoking and Biomarker 
Contrast 
Measure of Effect 
Kawai 
(2014)49 
Case-control. Seattle-Puget 
Sound metropolitan area. 
There were 960 cases and 
938 controls. Smoking 
exposure was obtained via 
questionnaire and restricted 
to those that occurred prior 
to reference date. Current 
and former smoking were 
not associated with TNBC 
breast cancer risk. 
 
ER+ or PR+: 
staining in ≥ 
1% of tumor 
cells. 
 
HER2+: FISH 
3+ 
TNBC: 
ER-/PR-
/HER2- 
 
 
 
 
Current vs. 
Never 
 
Former vs. 
Never 
 
TNBC vs.  
Controls 
 
TNBC vs.  
Controls 
OR and 95% CI  
1.2 (0.7 - 2.1) 
 
OR and 95% CI  
0.9 (0.6 - 1.5) 
 
Millikan 
(2008)13 
Case-control. The Carolina 
Breast Cancer Study. Study 
enrollment included 1,803 
cases and 1,564 controls. 
Data on smoking exposure 
was obtained during a 
nurse-administered 
interview. Smoking duration 
was not differentially 
associated with Luminal A 
or Basal-like breast cancer. 
 
Medical 
Records and 
IHC Staining 
Luminal A: 
ER+ and/or 
PR+, HER2- 
 
Basal-like: 
ER-, PR-, 
HER2-EGFR+ 
and/or CK 
5/6+ 
Years 
 
<10 
11-19 
20+ 
Never 
 
Basal-like vs. 
Luminal A 
OR (95% CI) 
 
0.9 (0.6 to 1.5) 
1.1 (0.7 to 1.7) 
0.7 (0.5 to 1.1) 
(Ref) 
 
Tariq 
(2014)50 
Prospective cohort. Tumor 
registry at the University of 
Florida at Jacksonville 
(2000-2005). Smoking 
status (ever = current or 
past) was recorded in the 
tumor registry and was not 
associated with TNBC 
tumors.  
 
Tumor registry TNBC: 
ER-/PR-
/HER2- 
Ever vs. Never 
 
 
TNBC vs.  
Non-TNBC 
 
 
Proportion  
20% vs. 28% 
p = 0.4 
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Reference Study Design and 
Overview 
Molecular Platform 
and definition  
of positive subtype 
Smoking and Biomarker 
Contrast 
Measure of Effect 
Turkoz 
(2013)51 
Cross-sectional. Department 
of Medical Oncology at 
Hacettepe University, 
Institute of Oncology. The 
study identified 1,884 
invasive cases that were 
eligible for analysis. 
Smoking exposure was 
obtained during physician-
led interview.  
 
ER+ or PR+: 
staining in ≥ 
5% of tumor 
cells. 
 
HER2+: FISH 
3+ 
Luminal:  
ER+ or PR+ 
 
TNBC: 
ER-/PR-
/HER2- 
 
 
Ever vs. Never 
 
 
Ever vs. Never 
Luminal vs. 
Non-Luminal 
 
TNBC vs. 
Non-TNBC 
OR and 95% CI  
1.0 (0.7 - 1.4) 
 
OR and 95% CI  
1.0 (0.7 - 1.4) 
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Table 2.3. Associations between smoking and risk of ER-defined breast cancer. 
Reference Study Design and 
Overview 
Molecular Platform 
and definition of 
positive subtype 
Smoking and Biomarker 
Contrast 
Measure of Effect 
Cooper 
(1989)52 
Case-control. Adelaide, 
South Australia. The study 
included 451 cases 
identified through the South 
Australian Central Cancer 
Registry between 1982 and 
1984. There were 451 age-
matched controls. Smoking 
exposure data was obtained 
in-person interview. Former 
smoking exposure was 
associated with increased 
risk of ER- breast cancer. 
Saturation 
analysis assay 
ER+: ≥ 10 
fmol/mg  
 
 
Current vs. 
Never 
 
Former vs. 
Never 
 
Current vs. 
Never 
 
Former vs. 
Never 
 
ER+ vs.  
Controls 
 
ER+ vs.  
Controls 
 
ER- vs.  
Controls 
 
ER- vs.  
Controls 
OR and 95% CI  
1.3 (0.8 - 2.0) 
 
OR and 95% CI  
0.9 (0.6 - 1.4) 
 
OR and 95% CI  
1.3 (0.7 - 2.5) 
 
OR and 95% CI  
1.9 (1.0 - 3.6) 
Gaudet 
(2013)53 
Cohort. The Cancer 
Prevention Study II (CPS-
II) Nutrition Cohort. 97,786 
women were enrolled in 
1992 to examine cancer 
incidence and mortality. 
Median follow-up was 14 
years 3,721 invasive breast 
cancers occurred. Both 
current and former smoking 
were associated with slight 
increased risks of breast 
cancer. Current and former 
smoking were associated 
with increased risk of ER+ 
breast cancer. However, 
neither were associated with 
risk of ER- breast cancer. 
 
Medical 
Records and 
Pathology 
Reports 
SEER (NOS) Current vs. 
Never 
 
Former vs. 
Never 
 
Current vs. 
Never 
 
Former vs. 
Never 
 
ER+ vs.  
Controls 
 
ER+ vs.  
Controls 
 
ER- vs.  
Controls 
 
ER- vs.  
Controls 
OR and 95% CI  
1.2 (1.0 - 1.5) 
 
OR and 95% CI  
1.1 (1.0 - 1.3) 
 
OR and 95% CI  
0.9 (0.5 - 1.4) 
 
OR and 95% CI  
1.0 (0.8 - 1.2) 
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Reference Study Design and 
Overview 
Molecular Platform 
and definition of 
positive subtype 
Smoking and Biomarker 
Contrast 
Measure of Effect 
Kabat 
(2011)48 
Cohort. The Women's 
Health Initiative (WHI). 
148,030 women aged 50-79 
were enrolled between 1993 
and 1998 and followed over 
an 8-year period. Smoking 
exposure was assessed at 
baseline via questionnaire. 
Former smokers had a slight 
increased risk of ER+ breast 
cancer. 
Medical 
Records and 
Pathology 
Reports 
ER+: NOS Current vs. 
Never 
 
Former vs. 
Never 
 
ER+ vs.  
Non-cases 
 
ER+ vs.  
Non-cases 
HR and 95% CI  
1.1 (0.9 - 1.3) 
 
HR and 95% CI  
1.1 (1.1 - 1.2) 
 
Kawai 
(2014)49 
Case-control. Seattle-Puget 
Sound metropolitan area. 
There were 960 cases and 
938 controls. Smoking 
exposure was obtained via 
questionnaire and restricted 
to those that occurred prior 
to reference date. Current 
and former smoking were 
associated with increased 
risk of ER+ breast cancer. 
Medical 
Records and 
Pathology 
Reports 
ER+: nuclear 
staining in ≥ 
1% of tumor 
cells. 
 
 
Current vs. 
Never 
 
Former vs. 
Never 
 
ER+ vs.  
Controls 
 
ER+ vs.  
Controls 
OR and 95% CI  
1.4 (1.0 - 1.9) 
 
OR and 95% CI  
1.3 (1.0 - 1.7) 
 
Manjer 
(2001)54 
 
 
 
 
 
 
 
 
Cohort. Malmo, Sweden. 
10,902 women born 
between 1926 and 1949 
with average age at 
enrollment of 50 years. 
Women were enrolled 
between 1974 and 1992 for 
average follow-up of 12 
years; 268 incident cases 
with available tumor tissue 
IHC ER+: Immuno-
reactivity 
Current vs. 
Never 
 
Former vs. 
Never 
 
Current vs. 
Never 
 
ER+ vs.  
Controls 
 
ER+ vs.  
Controls 
 
ER- vs.  
Controls 
 
 
RR and 95% CI  
0.9 (0.6 - 1.2) 
 
RR and 95% CI  
1.0 (0.7- 1.5) 
 
RR and 95% CI  
2.2 (1.2 - 4.0) 
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Reference Study Design and 
Overview 
Molecular Platform 
and definition of 
positive subtype 
Smoking and Biomarker 
Contrast 
Measure of Effect 
(continued) occurred. A self-
administered questionnaire 
was used to obtain data on 
smoking exposure. Current 
and former smoking 
exposure was associated 
with increased risk of ER-, 
but not ER+, breast cancer. 
 
Former vs. 
Never 
 
ER- vs.  
Controls 
RR and 95% CI  
2.7 (1.4 - 5.0) 
Morabia 
(1998)55 
Case-control. Geneva, 
Switzerland. 372 cases 
diagnosed between 1992 
and 1993; 1,059 controls 
were included. Data on 
smoking exposure was 
obtained during in-person 
interview. Ever smokers 
who smoked 20 or more 
cigarettes per day were at 
increased risk of developing 
ER+ and ER- breast cancer. 
IHC ER+: nuclear 
staining in ≥ 
20% of tumor 
cells. 
 
 
Ever 20+ cpd 
vs. Never 
 
Ever 20+ cpd 
vs. Never 
 
ER+ vs.  
Controls 
 
ER- vs.  
Controls 
OR and 95% CI  
2.4 (1.4 - 4.5) 
 
OR and 95% CI  
4.3 (1.4 - 13.0) 
 
Nishino 
(2014)56 
Case-control. Miyagi 
Cancer Center Hospital. 
1,309 breast cancer cases 
and 3,878 controls. 
Smoking exposure was 
assessed via questionnaire. 
Current or former smoking 
was not associated with 
either of the 4 ER/PR 
subtypes.  
Medical 
Records and 
Pathology 
Reports 
 
IHC and EIA 
ER+/PR+: 
NOS 
Current vs. 
Never 
ER+/PR+ vs. 
Controls 
 
ER+/PR-vs. 
Controls 
 
ER+/PR-vs. 
Controls 
 
ER-/PR- vs. 
Controls 
Null Associations for current 
and former smoking for all 
combinations of ER+/- and 
PR+/-. 
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Reference Study Design and 
Overview 
Molecular Platform 
and definition of 
positive subtype 
Smoking and Biomarker 
Contrast 
Measure of Effect 
Nyante 
(2014)44 
Cohort. AARP (formerly 
American Association of 
Retired Persons). 186,150 
female study participants 
were enrolled in 1995-96 
and followed for an average 
of 10 years. Smoking 
exposure was assessed via 
baseline questionnaire.  
SEER Cancer 
Registry 
ER+/PR+: 
NOS 
Current vs. 
Never 
 
Current vs. 
Never 
 
Current vs. 
Never 
ER+/PR+ vs. 
Controls 
 
ER-/PR+ vs. 
Controls 
 
ER-/PR- vs. 
Controls 
 
 
 
OR and 95% CI  
1.0 (0.9 - 1.2) 
 
OR and 95% CI  
1.4 (1.0 - 1.8) 
 
OR and 95% CI  
1.1 (0.8 - 1.4) 
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Table 2.4. Associations between smoking and risk of p53-defined breast cancer. 
Reference Study Design and 
Overview 
Molecular Platform 
and definition of  
positive subtype 
Smoking and Biomarker 
Contrast 
Measure of Effect 
Conway 
(2002)57 
 
The Carolina Breast Cancer 
Study. 456 invasive breast 
cancer cases were evaluated 
for specific TP53 mutations. 
Of these, 108 breast cancers 
(or 24%) harbored specific 
TP53 mutations. 71% of 
mutations were missense; the 
remaining were deletions or 
insertions. Relative to non-
smokers, current smokers were 
more likely to harbor p53 
mutations. 
 
Gene 
Sequencing 
 
 
p53+: presence 
of somatic 
mutation in 
exons 4-8 
Current vs. 
Never 
 
Former vs. 
Never 
 
p53+ vs. p53- 
 
 
p53+ vs. p53- 
OR and 95% CI  
2.1 (1.2 - 3.8) 
 
OR and 95% CI  
0.6 (0.4 - 1.2) 
 
Furberg  
(2002)58 
The Carolina Breast Cancer 
Study. The authors examined 
smoking exposure in relation 
to overexpression of p53 
protein among 683 cases. 
There was no apparent 
association between smoking 
status and p53 tumor 
expression. The authors also 
investigated the associations 
between smoking dose, 
duration, and p53 expression 
and observed no apparent 
associations. 
 
IHC  p53+: dark 
nuclear protein 
staining in ≥ 
10% of tumor 
cells. 
Current vs. 
Never 
 
Former vs. 
Never 
 
p53+ vs. p53- 
 
 
p53+ vs. p53- 
OR and 95% CI  
0.8 (0.6 - 1.3) 
 
OR and 95% CI  
1.0 (0.7 - 1.4) 
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Reference Study Design and 
Overview 
Molecular Platform 
and definition of  
positive subtype 
Smoking and Biomarker 
Contrast 
Measure of Effect 
Gammon 
(1999)59 
The Long Island Breast Cancer 
Study. Investigators examined 
the prevalence of p53 
overexpression in breast 
tissues of young women (age < 
45 years). Current smoking - 
but not former smoking - was 
associated with increased risk 
of p53 overexpression in breast 
tumors.  
 
IHC p53+: 
moderate to 
strong nuclear 
protein 
staining in ≥ 
10% of tumor 
cells. 
Current vs. 
Never 
 
Former vs. 
Never 
 
p53+ vs. p53- 
 
 
p53+ vs. p53- 
OR and 95% CI 
2.0 (1.1 - 3.5) 
 
OR and 95% CI 
1.4 (0.8 - 2.4) 
 
Mordukhovich 
(2010)60 
The Long Island Breast Cancer 
Study Project. 859 invasive 
breast tumors were evaluated 
for TP53 mutations (exons 5 - 
8). Of these, 151 harbored a 
p53 mutation. Current and 
former smokers were slightly 
less likely to have a p53 
mutation, when compared with 
never smokers. 
 
Gene 
Sequencing 
p53+: presence 
of somatic 
mutation in 
exons 5-8 
Current vs. 
Never 
 
Former vs. 
Never 
 
p53+ vs. p53- 
 
 
p53+ vs. p53- 
OR and 95% CI 
0.7 (0.4 - 1.2) 
 
OR and 95% CI 
0.9 (0.6 - 1.4) 
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CHAPTER 3: METHODS 
3.1 Overview 
Breast cancer is not a single disease, but exists as a collection of genetically distinct 
subtypes. These subtypes have prognostic and predictive value in clinical settings and may 
also provide clues to breast cancer etiology. Homogenous classifications of breast cancer 
may have masked associations in prior studies of smoking and breast cancer risk; thus, a 
critical examination would benefit by evaluating smoking in relation to etiologically-relevant 
subtypes. In addition, it is important to consider dose and timing of exposure. By examining 
temporal and dose-dependent patterns of smoking, we may identify etiologically-relevant 
time periods that are associated with risk of specific breast cancer subtypes. Using data from 
phase III of the Carolina Breast Cancer Study (CBCS III), we seek to examine temporal and 
dose-dependent relationships between smoking exposure, breast cancer intrinsic subtype, and 
breast tumor expression of biomarkers linked to pathogenesis. Phase III is a case only study 
of approximately 3,000 women diagnosed with invasive breast cancer between 2008 and 
2013 in central and eastern North Carolina. The CBCS includes self-reported data on 
smoking exposure and biomarker data obtained from tumor specimens, including protein and 
RNA expression data on genes with suspected links between smoking and breast 
carcinogenesis.  
3.2 Study Design 
Phase III of the Carolina Breast Cancer Study (CBCS) is a population-based case-
only study that combines epidemiology and molecular biology to examine environmental and 
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genetic risk factors for breast cancer. Breast cancer cases were identified by a rapid case 
ascertainment system, implemented through collaboration between Lineberger 
Comprehensive Cancer Center (LCCC) and the North Carolina Central Cancer Registry 
(NCCCR). To be eligible for inclusion, patients must have been female and received a first 
and primary diagnosis of breast cancer between May 1, 2008 and October 31, 2013. The 
patient also must have resided in the 44-county study region and been between the ages of 20 
and 74 at the time of diagnosis.  
To examine potential risk factor differences by age and race, the CBCS employed a 
randomized recruitment strategy that was designed to oversample young and African 
American women. The patient’s primary physician was contacted to obtain permission to 
invite the patient into the study and the overall expected response rate is 70%. Patients who 
declined participation were not substantially different from those who chose to participate in 
the study. In total, 2,998 women were enrolled in CBCS III. Study participants were asked to 
consent to a nurse-administered in-person interview that took place in the study participant’s 
home or another pre-arranged location. During the in-person interview the nurse 
administered a questionnaire that included items on family and personal medical history, 
reproductive history, smoking, alcohol, diet, medication use and occupational history. Upon 
consent, the nurse also collected a blood sample and objective anthropometric measurements 
of height (m), weight (kg, waist (m), and hip (m) circumference. The average time between 
study enrollment and interview was 6 months.  
At the time of interview, study participants were asked permission to obtain formalin-
fixed, paraffin-embedded (FPPE) tumor blocks or tissue slides from the hospital where the 
diagnostic surgery was to be performed. Participants were also asked for permission to obtain 
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pathology reports and medical records from the treating facilities. Clinical and pathological 
data abstracted from medical records and pathology reports included tumor size, stage, and 
node status. For all cases, a single pathologist (Dr. Joseph Geradts) determined tumor grade. 
3.3 Outcome Assessment 
The CBCS includes protein and RNA expression data on genes used to define 
intrinsic subtype and genes involved in mechanistic pathways that may link smoking to 
breast cancer risk (Table 3.1). We will examine binary and continuous outcomes of 
biomarker expression for intrinsic, estrogen-mediated, genotoxic, and growth-factor 
dependent mechanistic pathways. Specifically, we will use gene expression signatures and 
protein-specific cut points to characterize tumors as positive (+) or negative (-) for the given 
biomarker or biomarker pathways. We will use continuous measures of protein and counts of 
RNA transcripts to examine whether smoking exposure modulates biomarker expression. 
Tissue microarrays (TMAs) were constructed for immunohistochemical (IHC) staining of 
estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-
2 (HER2), cytokeratin 5/6 (CK 5/6), epidermal growth factor receptor (EGFR), and p53. 
Automated quantification of staining was performed using Genie classifier and protein-
specific algorithms61. RNA was extracted from the same tumor specimens used to construct 
the TMAs, using the Qiagen RNeasy FFPE kit and protocol. RNA expression data were 
obtained via Nanostring assay. TMA construction and IHC analyses were conducted at 
Tissue Pathology Laboratory (TPL) and the Immunohistochemical Core Laboratory (ICL) at 
UNC Chapel Hill. Nanostring assays were performed in the laboratory of Dr. Melissa 
Troester.  
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Table 3.1. Molecular characterization of breast tumors in CBCS III 
 
S
p
ec
if
ic
 A
im
s Specific 
Aims 
Aim 1 Aim 2 
Pathway a. Intrinsic 
b. Estrogen-
Mediated 
a. Genotoxic 
b. Growth-Factor 
Dependent 
Biomarker 
comparison 
Luminal vs. Basal ER+ vs. ER- p53+ vs. p53- 
EGFR+ vs. 
EGFR- 
M
o
le
cu
la
r 
C
h
a
ra
ct
er
iz
a
ti
o
n
 
Single gene  
IHC 
Nielsen37 
(2004) 
Hammond62 
(2010) 
Williams63  
(2017) 
10% 
Single gene 
mRNA 
N/A Continuous NA Continuous 
Multigene 
IHC 
signature 
Nielsen37 
(2004) 
NA NA NA 
Multigene 
mRNA 
signature 
Parker64 
(2009) 
NA 
Troester65 
(2006) 
NA 
 
Note. NA-Not Applicable 
 
3.3.1 Intrinsic subtype, multigene mRNA and IHC biomarkers 
Breast cancer intrinsic subtype was measured using the RNA-based “PAM50 
signature”64. Here, differential expression of the 50-gene signature is used to categorize 
breast cancers into 4 intrinsic subtypes: Luminal A, Luminal B, HER2E, and Basal-like. 
Each case was classified based upon highest Pearson correlation with a centroid defined for 
each subtype. For the analyses outlined in this proposal, we combined Luminal A, Luminal 
B, and HER2E tumors, since each have suspected luminal epithelial origins and may 
represent a single etiologic subtype8. Together, these tumors represent the Luminal breast 
cancer intrinsic subtype and will be compared to Basal-like breast tumors. 
The joint expression of five clinical markers was used to define IHC intrinsic 
subtypes. These markers include: ER, PR, HER2, CK 5/6, and EGFR. Each marker is 
designated as positive (+) or negative (-), based on clinicopathologic cut points for 
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overexpression. Automated quantification of ER and PR protein expression was determined 
by Genie classifier and the Aperio nuclear v9 algorithm; HER2 and EGFR quantification was 
determined using the Aperio membrane v9 algorithm (Aperio Technologies, Vista, CA). 
Definiens Tissue Studio® was used to quantify CK5/6 staining. Intrinsic subtypes were 
designated as follows: Luminal breast cancers were defined as (ER+ and/or PR+, regardless 
of HER2 status); and Basal-like tumors were defined as (ER-, PR-, HER2-, EGFR+ and/or 
CK5/6+). We will compare Luminal and Basal-like breast tumors.  
3.3.2 Estrogen-mediated biomarkers 
We will use a cut point of ≥ 1% of tumor cells with nuclear protein staining for ER to 
define borderline/positive ER status, as recommended by the American Society of Clinical 
Oncology (ASCO) and College of American Pathologists (CAP)62.  Specifically, we will 
define tumors with 1% to < 10% expression as ‘borderline positive’ and tumors with ≥ 10% 
expression as ‘positive’. Automated quantification of ER protein expression was determined 
by a Genie classifier and the Aperio nuclear v9 algorithm (Aperio Technologies, Vista, CA). 
In addition, we will examine quantiles and continuous measures of ER protein staining in 
relation to smoking exposure. Specifically, we will examine whether smoking exposure 
modulates protein expression of ER in breast tumors. We will also examine whether smoking 
exposure modulates ER mRNA expression.  
3.3.3 Genotoxic biomarkers 
We will use the 48-gene signature identified by Troester et al. to classify breast 
tumors as p53 wildtype or p53 mutant65. The 48-gene predictor is applied to each case and 
classified based upon highest Pearson correlation with a centroid defined for either subtype. 
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The mutant or wildtype designations characterize downstream biologic activity following 
p53 loss or activation, respectively.  
We will use a cut point of ≥ 10% of tumor cells with nuclear protein staining for p53 
as described by Williams et al.63. Automated quantification of p53 protein expression was 
determined by a Genie classifier and the Aperio nuclear v9 algorithm (Aperio Technologies, 
Vista, CA). As described above for ER protein staining, we will also examine continuous 
measures of p53 protein staining in relation to smoking exposure. 
3.3.4 Growth-factor dependent biomarkers 
We will explore the relationships between categorical and continuous measures of 
EGFR protein and RNA and measures of smoking exposure. Automated quantification of 
EGFR protein expression was determined by a Genie classifier and the Aperio membrane v9 
algorithm (Aperio Technologies, Vista, CA).  
3.4 Exposure Assessment 
History of smoking exposure was obtained during a nurse-administered in-person 
interview and includes data on smoking duration, frequency, and dose. Self-reported smoking 
is considered a valid measure of smoking exposure, with increased accuracy obtained during 
in-person interview formats66. Women in CBCS were considered ever smokers if they 
smoked at least 100 cigarettes during their lifetimes. CBCS investigators collected data on 
smoking history defined as ‘ever’ or ‘never’ (history); smoking status defined as ‘current’, 
‘former’, or ‘never’ (status); age at smoking initiation measured in years (initiation); smoking 
duration measured as the total number of years of smoking between initiation and current use 
or cessation (duration); number of cigarettes smoked per day (dose); and age at smoking 
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cessation, where applicable (recency). Together, these data will be used to derive categorical, 
ordinal, and continuous measures of smoking (e.g. pack-years).  
3.5 Covariate Assessment 
We selected potential confounders of the relationship between smoking and breast 
cancer risk based on a review of the literature. These include: 1. First-degree family history 
of breast cancer defined as breast cancer diagnosis for mother or full female siblings16; 2. 
Alcohol consumption defined as number of drinks consumed per week15,17,67; 3. Breast 
feeding characterized by age at first breast feeding13; 4. Body Mass Index (BMI kg/m2)13; 5. 
Income to family ratio calculated as the household income divided by the number present in 
the household68; 6. Parity defined as number of full-term births13,15; 7. Years of oral 
contraceptive use10; 8. Years of hormone replacement therapy use10; 9. Physical activity; 10. 
Age; and 11. Race.  
To identify a minimal adjustment set among the eleven potential confounders, we 
conducted directed acyclic graph analysis using DAGitty software (version 2.3). The smallest 
minimal adjustment set is as follows: alcohol, breast feeding, family history, income, parity, 
physical activity, age, and race. For continuous variables, we will explore various coding 
modalities to identify the coding scheme that results in the best fit and most parsimonious 
model. Covariates will be included in regression models as confounders based on whether 
there is a 10% or greater change in estimate when added to the model.  
3.6 Data Analysis 
This study examines the relationships between smoking, breast cancer intrinsic 
subtype, and biomarkers linked to pathogenesis. Specifically, we will examine smoking’s 
temporal and dose-dependent associations with PAM50 subtype (Aim 1a) and breast tumor 
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expression of biomarkers linked to estrogen-mediated (Aim 1b), genotoxic (Aim 2a), and 
growth-factor mediated (Aim 2b) pathways. The examination of temporal and dose-
dependent patterns of smoking in relation to biomarker-defined subtypes may identify 
exposure-time-windows that are associated with specific mechanistic events.  
3.6.1 Linear and logistic regression models   
 
We will use linear regression to model the relationship between smoking exposure 
and continuous measures of protein or RNA expression. We will test assumptions of linearity 
by examining higher order polynomials of smoking exposure. Smoking exposure will be 
modeled as a continuous measure of pack-years, defined as the product of the number of 
cigarettes smoked per day (dose) and the total number of years smoked (duration). We will 
examine the association between pack-years and biomarker expression defined as weighted 
percent cells of positive and the b) H-score. An H-score is a weighted measure of the number 
of weakly (1), moderate (2), and strongly stained (3) cells in the tissue sample and the ranges 
between 0 and 300. In addition to measures of percent positivity we will also examine pack-
years in relation to quantiles of gene expression using generalized logit models with ordinal 
outcomes. 
3.6.2 Binary outcomes and categorical measures of smoking  
For each binary breast cancer classification, we will use generalized logit models to 
estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the relationship between 
smoking exposure and subtype-specific breast cancer risk. This analysis will consider 
cumulative measures of smoking exposure. Breast cancer characterizations are described in 
Table 3.1.  
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3.6.3 Cumulative smoking exposure and time-windows analysis 
 For each binary breast cancer classification, we will use generalized logit models to 
estimate ORs and 95% CIs for risk of breast cancer subtype defined as a trend per pack-year 
for a) cumulative pack-years smoked and b) within exposure-time-windows defined by time 
since exposure. c) We will also use latency functions and associated graphs to visualize the 
temporal relation between smoking exposure and subtype-specific breast cancer risk. 
Evidence of an association between smoking and breast cancer risk proximal to time of 
diagnosis may allow us to infer that smoking is associated with a cancer promotion event for 
a given biomarker pathway. By contrast, if smoking exposure is associated with breast cancer 
risk at a distal point from date of diagnosis, we may infer that smoking is associated with 
cancer initiation or promotion events. Previous case-control studies of smoking and breast 
cancer risk have described an increased risk of disease among women who quit smoking 5 to 
10 years prior to date of case/control selection42. For our analysis, we selected three time-
windows that would accommodate available sample size: <10 years; 10-20 years; > 20 years. 
We will conduct likelihood ratio tests to determine whether our time windows analyses 
improve model fit, when compared cumulative exposure models.  
3.6.4 Parametric latency functions of smoking and breast cancer risk 
For each binary breast cancer classification, we will use generalized logit models with 
parametric latency functions to estimate ORs and 95% CIs for risk of breast cancer subtype. 
We emphasize recency of exposure in this analysis, and we hypothesize that associations 
between smoking exposure proximal or distal to date of diagnosis may differ across 
biomarker-defined subtypes. The inclusion of a parametric latency function in our logistic 
regression model will allow us to calculate time weighted exposure estimates using 
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maximum likelihood estimation (MLE); the highest weights are assigned during the time 
period where smoking is associated with the greatest risk of subtype-specific breast cancer. 
That is, our modeling strategy will allow us to identify peak risk according to recency of 
exposure for each biomarker-defined breast cancer type. We will examine hierarchical 
models with bilinear and log-normal latency functions. If our B-spline from analysis 2c 
demonstrates a multimodal relationship between smoking exposure and breast cancer risk, 
we will explore different probability distributions for our parametric latency function.  
 
3.7 Power Analysis 
 For all power calculations, we treat smoking exposure as a time-invariant variable, 
dichotomized as ‘ever smoker’ vs. ‘never smoker’. Based on smoking prevalence in CBCS 
phases I and II, we estimate that approximately 50% of women in phase III will have a 
history of ever smoking. For each binary breast cancer classification, we calculated the 
power to detect a statistically significant association for a theoretical range of case only odds 
ratio comparing smoking exposure and odds of having breast cancer subtypes: luminal vs. 
basal, ER+ vs. ER-, p53+ vs. p53-, and EGFR+ vs. EGFR-. IHC data will be available for the 
entire CBCS III study population (n=2,000) and RNA data will be available for a subset of 
study participants (n=1,000). (Recall that RNA data include gene signatures and counts of 
single RNA transcripts.) Table 3.2 describes the expected distributions of subtypes in CBCS 
III. Early estimates from phase III demonstrate a distribution of 4:1 for Luminal vs. Basal-
like; 4:1 for ER+ vs. ER-; 1: 2 for p53+ vs. p53-; and 1:3 for EGFR+ vs. EGFR-. Figure 1 
displays power distributions for a theoretical range of odds ratios for IHC and RNA 
measurements and each case-case comparison. Power calculations were performed in SAS 
9.4 (SAS Institute Inc., Cary, NC). 
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Table 3.2. Expected distributions of subtypes in CBCS III. 
Specific Aim Contrast Ratio* 
Aim 1a. Luminal vs. Basal 4:1 
Aim 1b. ER+ vs. ER- 4:1 
Aim 2a. p53+ vs. p53- 1:2 
Aim 2b. EGFR+ vs. EGFR- 1:3 
 
*Rounded to the nearest whole number. 
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Figure 3.1. Power distributions for theoretical case-case odds ratio. 
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3.8 Summary 
3.8.1 Limitations  
Although our study has several benefits, it is important to acknowledge limitations. 
The CBCS III study design did not include the recruitment of a control group that could be 
used to assess the baseline exposure distribution. Thus, our case-case odds ratios use a subset 
of cases as the referent group and the distribution of smoking exposure in this group may not 
reflect that of the population from which the case groups arise. To address this potential 
pitfall, we will perform a sensitivity analysis using controls from CBCS phases I and II. 
Controls from these study time periods were enrolled between 1993 and 2001. Cases in phase 
III were enrolled between 2008 and 2013. We will use generalized logistic regression 
functions with polytomous outcomes to calculate both case-control and case-case odds ratios. 
If the case-case odds ratios in our sensitivity analysis are similar to those which are observed 
in our phase III case-only analysis, we may infer that controls from the early phases are 
exchangeable for controls that would have been collected for phase III and are suitable to be 
used in phase III to evaluate associations between risk factors and subtype-specific breast 
cancer risk. If the case-case odds ratios from the primary and sensitivity analyses are not 
comparable, we will report the case-case odds ratios and include a detailed description of this 
limitation.  
3.8.2 Strengths 
 With the unique compilation of observational and breast tumor biomarker data, CBCS 
is an idea resource to examine the association between smoking and breast tumor biomarkers 
linked to pathogenesis. By examining temporal relationships between smoking and breast 
cancer risk, we may identify exposure-time-windows that are most critical for disease 
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development. Further, examining temporal patterns of smoking in relation to biomarker-
defined breast cancers may allow us to infer whether the expression of a given biomarker is 
associated with smoking exposures that are proximal or distal to time of diagnosis. Together, 
the strengths of this study may help to elucidate associations masked in prior investigations.  
3.9 Addendum 
During the conceptualization of the dissertation research, we planned to evaluate 
protein biomarker intensity in the form of an H-Score. However, due to properties of the 
staining protocol and automated quantification, it was difficult to distinguish cells that were 
stained at 2+ intensity vs. 3+ intensity. Thus, we focused our analyses on counts of cells that 
stained positive for the antigen.  
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CHAPTER 4: SMOKING AND ESTROGEN-MEDIATED BIOMARKERS 
 
4.1 Introduction 
Epidemiologic studies have demonstrated distinct risk factor profiles for breast cancer 
subtypes classified according to estrogen-receptor (ER) status11,13. Defined by an 
immunohistochemical (IHC) threshold of 1 to 10 percent staining of examined tumor cells, 
ER-positive (+) breast tumors account for more than 70% of all breast cancer cases 
diagnosed in the United States (US), making this disease group an important public health 
focus4,62. Pre-diagnostic smoking exposure has been linked to the ER+ subtype in some 
epidemiologic studies, with increased risks ranging between 10% to 50%44,49,69. Further, 
prospective studies of breast cancer survivors have suggested that smoking exposure prior to 
diagnosis may influence survival outcomes, particularly among women with ER+ disease, 
and presumably through reduced efficacy of anti-estrogenic therapies. For example, in a 
prospective study of Swedish breast cancer patients, ER+ women who smoked before 
diagnosis and who were treated with an aromatase inhibitor (AI) had a 3-fold increased risk 
of experiencing distant metastases or death, when compared to ER+/AI-treated non-smokers 
[Hazard Ratio (HR) and 95% CI (3.0 and 1.4 to 6.1)]70. Together, these epidemiologic and 
clinical findings could be used to suggest that smoking exposure may be linked to estrogen 
metabolism in breast tumors and subsequent regulation of ER.  
Although growing evidence suggests smoking as a possible risk factor for breast 
cancer, the mechanistic events leading to breast tumor initiation or promotion have not been 
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clearly defined71. Thus, if smoking is linked to breast cancer via estrogen-mediated 
pathways, it is plausible that quantitative levels of ER may differ between breast tumors of 
smokers and non-smokers. However, IHC assays are highly sensitive for the detection of ER 
leading to saturated signals and suppression of ER’s dynamic range for gene expression72. 
RNA assays, which are less susceptible to saturation, may allow for improved assessments of 
smoking and quantitative ESR1 expression. In addition, multigene scores such as the PAM50 
Luminal gene signature64,72 reflect cross-sectional measures of estrogen-signaling in breast 
tumors, and may offer improved resolution when examining smoking in relation to ER 
expression. 
Binary classifications of breast tumors with respect to ER status represent two distinct 
classes of disease characterized by age-incidence patterns and cells of origin (i.e., ER+ vs. 
ER–)7. As such, subtype-specific evaluations of smoking and breast cancer risk have 
demonstrated possible links to the ER+ etiologic type, but may mask quantitative 
associations between smoking and continuous measures of ER within tumors. In this study, 
we sought to evaluate smoking and its association with binary classifications and quantitative 
measures for ER protein, ESR1 mRNA, and a multigene score that serves as a cross-sectional 
measure of estrogen-signaling patterns in tumors; we examined temporal and dose-dependent 
measures of smoking in relation to each biomarker. Findings from our study may have 
implications for future studies that seek to evaluate smoking exposure in relation to 
hypothesized etiologic biomarkers in breast tumors. 
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4.2 Methods 
4.2.1 Study Population 
Phase III of the Carolina Breast Cancer Study (CBCS III) is a population-based case-
only study that combines epidemiology and molecular biology to examine environmental and 
genetic risk factors for molecular subtypes of breast cancer. To be eligible for inclusion, 
patients must have been female and received a first and primary diagnosis of breast cancer 
between May 1, 2008 and October 31, 2013. The patient also must have resided in the 44-
county study region and been between the ages of 20 and 74 at the time of diagnosis. To 
examine potential risk factor differences by age and race, the CBCS employed a randomized 
recruitment strategy that was designed to oversample young and African American women73.  
Breast cancer cases were identified by a rapid case ascertainment system, 
implemented through collaboration between Lineberger Comprehensive Cancer Center 
(LCCC) and the North Carolina Central Cancer Registry (NCCCR). Briefly, CBCS contacted 
the patient’s primary physician to obtain permission to invite the patient into the study, 
yielding an overall response rate of 70% and a total of 2,998 women. Study participants were 
asked to consent to a nurse-administered in-person interview that took place in the study 
participant’s home or another pre-arranged location. The average time between study 
enrollment and interview was 6 months. The nurse administered questionnaire included items 
on family and personal medical history, reproductive history, smoking, alcohol, diet, 
medication use and occupational history. Upon consent, the nurse also collected a blood 
sample and objective anthropometric measurements of height (m), weight (kg, waist (m), and 
hip (m) circumference.  
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4.2.2 Study Design 
Outcome Assessment  
The CBCS includes protein and RNA expression data on genes involved in estrogen-
signaling. At the time of interview, investigators asked study participants for permission to 
obtain formalin-fixed, paraffin-embedded (FPPE) tumor blocks or tissue slides from the 
hospital where the diagnostic surgery was to be performed. Tumor blocks were used to 
construct tissue microarrays (TMAs) for IHC staining, where each patient’s tumor was 
represented by 1 to 8 cores on the microarray. RNA was extracted from the same tumor 
specimens used to construct the TMAs, using the Qiagen RNeasy FFPE kit and protocol. 
CBCS includes data for 1970 women included in the IHC analysis and 1,011 women 
included in the RNA analysis. 
 Estrogen receptor protein. Automated quantification of ER protein was determined 
by a Genie classifier and the Aperio nuclear v9 algorithm (Aperio Technologies, Vista, 
CA)61. We calculated percent positivity for ER as the product of positively stained tumor 
cells for each core, multiplied by its core-specific weight, summed across all cores per patient 
(ER WT%). We assigned a cut point of ≥ 10% for ‘ER positive’ tumors; 1% to < 10% for 
‘ER borderline’ tumors; and < 1% for ‘ER negative’ tumors. For the ER binary classification, 
‘ER borderline’ tumors were combined with ‘ER negative tumors’. 
ESR1 mRNA. ESR1 was quantified using Nanostring technology. Briefly, total ESR1 
mRNA counts were assayed using an ESR1-specific molecular probe, which hybridizes to 
RNA fragments in solution. Hybrids are then counted using microscopic imaging, yielding 
raw mRNA counts. Quality control and data normalization were performed using the 
NanostringNorm R package74. Data were first normalized to the geometric means of 6 
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internal positive controls and subsequently to the geometric means of 5 reference genes. 
Normalized ESR1 counts were log2 transformed, yielding a bimodal Gaussian distribution of 
the data. We used the mclust R package to classify the two distributions as ESR1– or ESR1+, 
reflecting low and high expression, respectively75. ESR1- tumors had log2 values ranging 
between 0 to 8.35 and ESR1+ tumors had log2 values ranging between 8.38 to 15.64.  
Luminal Score. The PAM50 Luminal gene signature includes 8 highly correlated 
genes associated with Luminal type breast cancers, and which are characterized by ER 
expression64,72. The 8 genes include: BAG1, ESR1, FOXA1, GPR160, NAT1, MAPT, 
MLPH, and PGR. Each gene was quantified and normalized according to procedures for 
ESR1, as described above. To calculate the Luminal Score (LS), we took the average of the 
normalized values of the 8 genes. Normalized and transformed values for LS followed a 
bimodal Gaussian distribution. We used the mclust R package to classify the Luminal Score 
as LS– or LS+, reflecting low and high scores, respectively. LS– tumors had log2 values 
ranging between 3.26 to 7.57 and LS+ tumors had log2 values ranging between 7.58 to 
11.37. ESR1 mRNA and the 8 genes embedded in the Luminal Score were assayed along 
with other genes included in 1 of 3 Nanostring batches or code sets. Thus, all Nanostring 
analyses were adjusted for ‘code set’ in order to minimize potential batch effects.  
Exposure Assessment 
History of smoking exposure was obtained during the nurse-administered in-person 
interview and includes data on smoking duration, frequency, and dose. Self-reported smoking 
is considered a valid measure of smoking exposure, with increased accuracy obtained during 
in-person interview formats66. Women in CBCS were considered ever smokers if they 
smoked at least 100 cigarettes during their lifetimes. CBCS investigators collected data on 
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smoking history defined as ‘ever’ or ‘never’ (history); smoking status defined as ‘current’, 
‘former’, or ‘never’ (status); age at smoking initiation measured in years (initiation); smoking 
duration measured as the total number of years of smoking between initiation and current use 
or cessation (duration); number of cigarettes smoked per day (dose); and age at smoking 
cessation, where applicable. Pack-years were defined as a cumulative measure of the number 
of cigarette packs smoked per day, divided by smoking duration in years. Similarly, pack-
decades were defined as a cumulative measures of cigarette packs smoked per day, over 10-
year intervals. 
Covariate Assessment 
We selected potential confounders of the relationship between smoking and breast 
cancer risk based on established risk factors for breast cancer and study design variables. 
Potential confounders include: first-degree family history of breast cancer defined as breast 
cancer diagnosis for mother or a full female sibling16; alcohol consumption defined as having 
any history of alcohol use15,17,67; ever having breast fed 13; body mass index (BMI kg/m2)13; 
parity defined as number of full-term births13,15; history of oral contraceptive use10; hormone 
replacement therapy use10; menopausal status; meeting physical activity guidelines; age; and 
race.  
Participants were also asked for permission to obtain pathology reports and medical 
records from the treating facilities. Clinical and pathological data abstracted from medical 
records and pathology reports included tumor size, stage, and node status; these tumor 
characteristics were considered as potential confounders of the relationship between smoking 
and ER expression. For all cases, a single pathologist (Dr. Joseph Geradts) determined tumor 
grade. 
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4.2.3 Data Analysis 
For each binary breast cancer classification, we used generalized logit models to 
estimate odds ratios (ORs) and 95% confidence intervals (CIs) for categorical measures of 
smoking and the ER, ESR1, and LS-defined subtypes. To evaluate temporal and dose-
dependent associations between smoking and subtype, we first estimated the associations via 
logistic regression for a one unit increase in pack-decades, defined as the number of cigarette 
packs smoked per day over a 10-year period. We compared this cumulative exposure model 
to an exposure-time-windows model (i.e., piecewise logistic regression model) for three 
windows, with respect to time of diagnosis: < 10 years; 11-20 years; and > 20 years. We used 
a likelihood ratio test (LRT) to compare the deviances between the two models, the 
difference of which follows a chi-square distribution with 2 degrees of freedom.  
To evaluate the hypothesis that odds of ER, ESR1, and LS-positive subtypes vary 
with time since smoking exposure, we used a generalized logit model with a lognormal 
latency function to calculate time weighted exposure estimates for the 40-year period 
preceding breast cancer diagnosis. The latency period between smoking exposure and breast 
cancer occurrence is thought to be as much as 40 years and the lognormal distribution has 
been used to describe variation in risk with time since exposure other studies of cancer 
etiology76. Specifically, the lognormal latency function can be used to describe the rise, peak, 
and decline in risk or log-odds with respect to time since exposure. The highest weights are 
assigned during the time interval where smoking is associated with the greatest odds of ER+, 
ESR1+, or LS+ breast cancer and may signify the most etiologically-relevant time interval 
for smoking exposure. The macro used to model the lognormal latency function is described 
in Richardson (2009)77.  
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We used linear regression to model the relationship between continuous measures of 
ER ESR1, LS and categorical measures of smoking, adjusted for age, race, and Nanostring 
code set (where applicable). We calculated the estimated value of continuous biomarker 
expression for each individual, based on coding of the smoking exposure and covariate 
pattern. To isolate the effect of each smoking measure, we subtracted the effects of age, race, 
and Nanostring code set from the overall expression level. Expression levels for each 
biomarker were described according to interquartile range and visualized using box plots 
within categories of smoking. 
All analyses were conducted using SAS 9.4 (SAS Institute Inc, Cary, NC) and R 
version 3.3.3.  
4.3 Results 
Figure 4.1 illustrates the relationships between categorical and continuous measures for 
luminal score, ESR1 mRNA, and ER protein. (A) The EM-algorithm identified distinct 
clusters for ESR1 and LS, reflecting low and high expression for each. We compared binary 
classifications for ER protein as measured by IHC to those for ESR1 and LS and observed 
moderate to good values for sensitivity (se) and specificity (sp) (ER vs. ESR1: se=92%, 
sp=86% and ER vs. LS: se=89%, sp=85%). (B) Weighted percent ER protein (ER WT%) 
was positively correlated with log2 values for ESR1 mRNA (r=0.70, p < 0.01). ESR1 mRNA 
appeared to have a greater dynamic range compared to ER WT% where values for ER+ 
tumors tended to saturate the upper end of the percentage range.  
Figure 4.2 displays estimated odds ratios and 95% confidence intervals for smoking 
and binary breast cancer classifications for ER, ESR1, and LS, adjusted for traditional breast 
cancer risk factors. (A) ER+ breast tumors were most common among ever smokers 
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compared to never smokers (OR = 1.51 95% CI: 1.15, 1.97). When stratified by smoking 
status at time of diagnosis, current smokers were twice as likely to be ER+ compared to 
never smokers (OR=1.89 95% CI: 1.33, 2.70); former smokers had an elevated, though 
statistically non-significant, odds of ER+ breast cancer (OR = 1.25 95% CI: 0.91, 1.73). In 
addition, smoking duration of 20 years or more was linked to elevated odds of ER+ breast 
cancer (OR = 1.79 95% CI: 1.26, 2.56). We also observed elevated odds of the ER+ subtype 
for shorter intervals of smoking, though estimates were statistically non-significant. Women 
who smoked ‘<1/2’ or ‘1/2 to 1’ packs of cigarettes per day had increased odds of ER+ breast 
cancer [(OR = 1.48 95% CI: 1.04, 2.10) and (OR = 1.57 95% CI: 1.09, 2.26), respectively]. 
However, for the highest category for smoking dose (> 1 pack/day), we observed an elevated 
but statistically non-significant odds for ER+ tumors (OR = 1.44 95% CI: 087, 2.37). With 
respect to ‘time since smoking’, smoking within 5 years of breast cancer diagnosis was 
associated with a 60% increased odds of having ER+ breast cancer (OR 1.59 95% CI 1.15, 
2.20). (B, C) In general, we observed similar patterns of association between smoking 
measures and the ESR1+ and LS+ subtypes. Notably, the magnitudes of the ORs were 
slightly higher for the RNA-based measures, particularly for smoking duration and time since 
smoking exposure.  
 Table 4.1 presents estimated ORs for cumulative smoking exposure overall and 
within exposure time-windows. Our cumulative exposure models demonstrated that a 1-unit 
increase in pack-decades was associated with a 10% to 18% increase in the odds of having a 
‘positive’ subtype: ER+ (OR = 1.09 95% CI: 0.99, 1.20), ESR1+ (OR = 1.18 95% CI: 1.04, 
1.34), and LS+ (OR = 1.18 95% CI: 1.04, 1.35). Moreover, for the exposure time-windows 
models, total pack-decades smoked within 10 years of a breast cancer diagnosis was 
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associated with the greatest odds of having ER+, ESR1+, or LS+ breast cancer when 
compared to exposure accumulated between 10 and 20 or greater than 20 years prior to 
diagnosis. However, results from our likelihood ratio test suggest that the exposure time-
windows model provides improved fit over the cumulative exposure model for LS-defined 
subtypes (LRT = 6.39, 2 df), but did not substantially improve data fit for the ER (LRT = 
0.94, 2df) and ESR1 subtypes (LRT = 2.59, 2 df).  
 Figure 4.3 illustrates variation with time-since-exposure for the association between 
pack-decades and LS+ breast cancer for the 40-year period preceding breast cancer 
diagnosis. Our latency model with lognormal weighted exposures demonstrated increased 
odds of the LS+ subtype for pre-diagnostic smoking proximal to time of diagnosis. A 
likelihood ratio test comparing the lognormal latency model to the cumulative exposure 
model for the same 40-year period did not suggest that our latency model provided improved 
fit for the data (LRT = 4.2, 2 df). However, the dose-response parameter estimate in our 
latency model was statistically significant, thereby suggesting the peak in odds proximal to 
diagnosis may be the most etiologically relevant time point for smoking and ER+ breast 
cancer occurrence.  
 Table 4.2 and Table 4.3 present estimated biomarker expression values for ER 
protein, ESR1 mRNA, and the luminal score, adjusted for age, race, and Nanostring code set 
(where applicable). In general, ER protein levels did not vary across smoking exposures for 
breast cancer cases overall or when restricted to ER+ cases. Compared to never smokers, we 
observed the highest levels of ESR1 mRNA and the luminal score among current smokers 
[(mean (log2) = 10.0 vs. 9.4, p = 0.02) and (mean (log2) = 8.8 vs. 8.5, p = 0.01), 
respectively]. When restricted to ER+ breast cancer cases, we still observed higher levels of 
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ESR1 among current smokers, however the luminal score value for this group was 
attenuated. Figure 4.4, Figure 4.5, and Figure 4.6 visualize distributions for each biomarker 
among ‘Never’, ‘Former’, and ‘Current’ smokers. 
4.4 Discussion 
Findings from our study lend support to the hypothesis that smoking could be linked 
to breast cancer via estrogen-mediated pathways. In our case-only study of nearly 2,000 
patients, we observed increased odds of the ER+ subtype for temporal and dose-dependent 
measures of smoking. We also demonstrate that these associations hold for ER-related 
subtypes characterized by ESR1 mRNA and a multigene luminal score (LS). Increased odds 
of ER+, ESR1+, and LS+ subtypes was most apparent among women who were self-reported 
current smokers at time of diagnosis. Logistic regression models with latency parameters 
allowed us to simultaneously model dose, duration, and time of exposure to demonstrate that 
the most etiologically relevant period for smoking and ER-defined breast cancer may be 
during pre-diagnostic smoking exposure proximal to time of diagnosis. In addition, we 
observed that current smoking was associated with increased quantitative levels for ESR1, 
but not ER protein, which may suggest that RNA more sensitively captures biological 
differences when compared to ER protein expression.  
 Contemporary epidemiologic studies have demonstrated positive associations 
between smoking and ER+ breast cancer with estimates ranging between 10%-50% increased 
risk among current or former smokers42,48,49,69. Our case-only analysis demonstrated a near 
doubling for the odds of having ER+ vs. ER- breast cancer among current smokers. These 
findings are complemented by our previous case-control analysis in the Carolina Breast 
Cancer Study, which showed increased risk of ER+ disease among smokers and 
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heterogeneity of ORs for the Luminal (ER+) and Basal-like (ER-) subtypes69,78. Notably, we 
observed a positive association between smoking and ER+ risk but no association between 
smoking and the ER- subtype in the case-control setting – a pattern which was observed in 
other studies performed in US populations. However – in stark contrast – older studies of 
smoking and breast cancer risk in Swedish, Swiss, and Australian populations have 
demonstrated positive associations between smoking and the ER- breast cancer 
subtype52,54,55. These conflicting observations may reflect temporal differences in exposure, 
behavioral patterns, or may also be an artifact of differing methods used to assay ER 
expression (e.g., ligand-binding, immunoreactivity). Thus, a careful investigation of the 
relationship between smoking and ER-defined breast cancer subtypes should consider era, 
methodological approaches, and characteristics of population of interest. 
In both clinical and research settings, immunohistochemistry has been used as the 
standard for estrogen-receptor quantification in breast tumors79. IHC is highly sensitive for 
the detection of ER protein, serving as an excellent marker of antigenicity, but may be less 
than ideal for accurate quantification of positively stained cells due to assay saturation and 
challenges of ER quantification by digital imaging. Our study addresses this potential 
limitation by using ESR1 mRNA counts assayed via Nanostring technology to characterize 
breast tumors as ESR1+ and ESR1-. Unlike ER expression values for percent positivity, the 
log2 transformed ESR1 mRNA counts in our study follow a bimodal Gaussian distribution, 
identifying two distinct classes of breast tumors reflecting low and high expression of ESR1. 
However, percent agreement between ER and ESR1 subtype classifications was good. And 
we observed similar patterns of association between smoking measures and the ER+ and 
ESR1+ subtypes, where current smoking, long smoking duration of more than 20 years, and 
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smoking within 5 years of a breast cancer diagnosis was associated with 2 to 3 times the odds 
of having a positive (+) subtype.  
In addition, our study benefits by the incorporation of a multigene luminal score 
embedded in the PAM50 signature, used to classify breast tumors according to intrinsic 
subtype64,72. The 8 genes included in the luminal score are highly correlated with Luminal 
subtypes, which are characterized by high estrogen-receptor expression. Multigene scores 
may offer improved resolution over single gene markers as these cross-sectional assessments 
are often predictive, prognostic, and may have etiologic relevance. We observed similar 
patterns of association between smoking and the LS subtypes though the magnitudes of 
association were slightly higher for the ESR1 and LS mRNA classifications.  
Although the prevalence of cigarette smoking has steadily decreased since the 1950s, 
approximately 50% of women in the United States report a history of ever smoking and 14% 
are self-reported current smokers21. For protracted exposures in studies of etiology, it is 
important to evaluate measures of dose, duration, and temporality in order to fully evaluate 
associations with the outcome. Women with the longest smoking histories in our study were 
older compared to never smokers and were also most likely to be self-reported current 
smokers at time of diagnosis. As such, traditional metrics for smoking in studies of cancer 
etiology are confounded by age, dose, and duration of exposure thereby creating a challenge 
in understanding how combination of dose and timing influence biomarker expression in 
breast tumors. 
In the present study, we use time constant (cumulative) and time-varying (latency) 
models to simultaneously evaluate dose, duration, and timing of exposure; we observed that 
pre-diagnostic smoking proximal to time of diagnosis may be associated with increased odds 
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of ER+, ESR1+, and LS+ subtypes. We also observed higher quantitative levels of ESR1 
among current smokers and women who smoked within 5 years of breast cancer diagnosis. In 
the absence of longitudinal measures for smoking and biomarker expression, this observation 
may allow us to hypothesize that smoking could be linked to promotion events, as opposed to 
initiation events that would likely be linked to more distal smoking exposures. Indeed, 
several clinical studies have reported decreased efficacy of both estrogenic therapy in 
postmenopausal women and antiestrogenic therapy among women with breast cancer, 
suggesting that smoking may interfere with estrogen metabolism. Researchers have also 
suggested that fluctuations in endogenous estrogens may influence intrinsic subtyping. Thus, 
it is plausible that exogenous exposures that influence estrogen metabolism may modulate 
estrogen-receptor expression, which may have implications for intrinsic subtyping of breast 
tumors among smokers. Interestingly, we did not observe associations between smoking and 
quantitative ER expression. Protein and mRNA reflect distinct processes in gene expression 
and also require differing methods for evaluation and quantification. The high sensitivity of 
ER IHC assays may yield this method less suitable for quantification of ER protein.  
With the unique compilation of observational and biomarker data, CBCS is an ideal 
resource to examine the association between smoking and ER-defined breast cancer 
subtypes. Findings from our study add a unique contribution to the body of literature by 
considering multiple methods to characterize ER-defined breast tumors and by incorporating 
measures of time, duration and dose to identify etiologically relevant exposure periods. We 
identified what may be an etiologically relevant exposure period for smoking proximal to 
time of diagnosis. And we also suggest that RNA measures may provide improved resolution 
of gene expression for studies seeking to evaluate the etiology of ER+ breast tumors. Future 
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work should seek to examine smoking in relation to other proposed biomarkers of breast 
carcinogenesis.  
4.5 Addendum 
When developing the analytic plan for Aim 1, we identified the possibility of 
evaluating smoking exposure in relation to the multigene luminal score, though it was not 
described in our initial methodology plan. In addition, we also examined associations 
between smoking and breast cancer intrinsic subtype; patterns of association comparing 
Luminal and Basal-like subtypes were similar to that for our luminal score comparisons (i.e., 
LS+ vs. LS-). We elected to present results for the luminal score measure and have omitted 
results for the intrinsic subtype comparisons.  With respect to estimated odds ratios, we 
adjusted for node status, tumor size, tumor stage, and tumor grade in addition to covariates 
described in Chapter 3. We hypothesized that these tumor characteristics may influence the 
expression of ER and ER-related genes.
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A.                                                                                                    B. 
 
Figure 4.1. Relationships between ER IHC status, ESR1 mRNA expression (log2), and luminal score (median-centered).  
Note. (A) ER positive breast tumors are colored yellow (≥10% weighted positivity); ER borderline tumors are colored gray (1% to < 10% weighted 
positivity); and ER negative tumors are colored dark blue (< 1% weighted positivity). (B) Scatterplot showing the relationship between ER weighted 
percent positivity (%), ESR1 mRNA expression (log2), and luminal score binary classifications (i.e., LS+ and LS-). ER IHC and ESR1 mRNA 
values were positively correlated (r=0.70, p <0.01). An expectation-maximization (EM) algorithm identified two distinct clusters for ESR1 
expression (ERS1-, dark blue; ESR1+, yellow). 
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Figure 4.2. Categorical smoking metrics and association with ER, ESR1, and LS breast cancer subtypes 
Note. (A) The association between smoking and ER+ breast cancer. Contrast compares ER+ cases to ER- cases with never smokers as referent group; 
(B) The association between smoking and ESR1+ breast cancer. Contrast compares ESR1+ cases to ESR1- cases with never smokers as referent group; 
(C) The association between smoking and LS+ breast cancer. Contrast compares LS+ cases to LS- cases with never smokers as referent group. Odds 
ratios and 95% confidence intervals were derived from unconditional logistic regression models, adjusted for: Nanostring batch, age, race, menopausal 
status, parity, breastfeeding, family history of breast cancer, alcohol use, body mass index (kg/m2), physical activity, oral contraceptive use, hormone 
replacement therapy use, node status, stage, tumor size, and tumor grade. 
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Note. (A) The association between smoking and ER+ breast cancer. Contrast compares ER+ cases to ER- cases with never smokers as referent group; 
(B) The association between smoking and ESR1+ breast cancer. Contrast compares ESR1+ cases to ESR1- cases with never smokers as referent group; 
(C) The association between smoking and LS+ breast cancer. Contrast compares LS+ cases to LS- cases with never smokers as referent group. Odds 
ratios and 95% confidence intervals were derived from unconditional logistic regression models, adjusted for: Nanostring batch, age, race, menopausal 
status, parity, breastfeeding, family history of breast cancer, alcohol use, body mass index (kg/m2), physical activity, oral contraceptive use, hormone 
replacement therapy use, node status, stage, tumor size, and tumor grade. 
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Note. (A) The association between smoking and ER+ breast cancer. Contrast compares ER+ cases to ER- cases with never smokers as referent group; (B) 
The association between smoking and ESR1+ breast cancer. Contrast compares ESR1+ cases to ESR1- cases with never smokers as referent group; (C) 
The association between smoking and LS+ breast cancer. Contrast compares LS+ cases to LS- cases with never smokers as referent group. Odds ratios 
and 95% confidence intervals were derived from unconditional logistic regression models, adjusted for: Nanostring batch, age, race, menopausal status, 
parity, breastfeeding, family history of breast cancer, alcohol use, body mass index (kg/m2), physical activity, oral contraceptive use, hormone replacement 
therapy use, node status, stage, tumor size, and tumor grade.  
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Table 4.1. Estimated odds ratios and 95% confidence intervals for cumulative smoking 
exposure and ER-defined breast cancer subtypes.  
 
 ER ESR1 LS 
 
OR per pack-decade 
 (95% CI) 
 OR per pack-decade 
 (95% CI) 
OR per pack-decade 
 (95% CI) 
    
Cumulative Exposure 1.09 (0.99, 1.20) 1.18 (1.04, 1.34) 1.18 (1.04, 1.35) 
Time Since Exposure     
0 - 10 years 1.54 (0.74, 3.19) 2.15 (0.82, 5.64) 2.99 (1.11, 8.08) 
10 - 20 years 0.83 (0.37, 1.89) 0.87 (0.30, 2.55) 0.79 (0.26, 2.35) 
20+ years 1.08 (0.88, 1.32) 1.07 (0.83, 1.39) 1.01 (0.78, 1.31) 
Test of heterogeneity     
LRT, 2 dfa 0.94 2.59 6.39 
p-value 0.63 0.27 0.04 
    
 
Abbreviations: ER-Estrogen-receptor. IHC-Immunohistochemistry. LRT- Likelihood Ratio Test. LS-Luminal 
Score. PS-Proliferation Score.  
Note. Smoking exposure was modeled as the number of packs smoked per decade. Odds ratios and 95% confidence 
intervals were derived from unconditional logistic regression models, adjusted for: Nanostring code set, age, race, 
menopausal status, parity, breastfeeding, family history of breast cancer, alcohol use, body mass index (kg/m2), 
physical activity, oral contraceptive use, hormone replacement therapy use, node status, stage, tumor size, and 
tumor grade.  
a - LRT comparing cumulative and exposure-time-windows model, with 2 degrees of freedom. 
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Figure 4.3. Temporal associations between pack-decades of cigarettes smoked and luminal score positive (LS+) breast cancer. 
Note. Logistic regression models were adjusted for age and race. The dashed blue line indicates the estimated odds ratio for cumulative smoking 
exposure (pack-decades) for the model described in Table 2 (OR and 95% CI = 1.18 (1.04, 1.35)). The solid dark gray dots indicate point estimates 
for the association between pack-decades and LS+ breast cancer for each year preceding breast cancer diagnosis over a period of 40 years, with 
exposure time points weighted using a lognormal distribution. The light gray bands represent 95% confidence intervals surrounding point 
estimates.   
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Table 4.2. Estimated biomarker expression values for the effect of categorical smoking 
measures.  
 ER  
(WT%) 
ESR1 mRNA 
(Log2) 
Luminal Score 
(Log2) 
Metric Mean ± SD p Mean ± SD p Mean ± SD p 
Smoking 
      
Never 56.6 ± 10.2 REF 9.4 ± 0.7 REF 8.5 ± 0.4 REF 
Ever 57.5 ± 9.6 0.05 9.7 ± 0.7 0.02 8.6 ± 0.4 0.04 
Smoking status 
      
Never 56.6 ± 10.2 REF 9.4 ± 0.7 REF 8.5 ± 0.4 REF 
Former 55.2 ± 9.4 0.11 9.4 ± 0.7 0.15 8.5 ± 0.4 0.38 
Current 60.8 ± 8.9 0.14 10.0 ± 0.6 0.02 8.8 ± 0.4 0.01 
Duration (years) 
      
Never 56.6 ± 10.3 REF 9.4 ± 0.7 REF 8.5 ± 0.4 REF 
≤10 years 59.0 ± 9.5 0.22 9.7 ± 0.7 0.32 8.6 ± 0.4 0.24 
11-20 years 60.0 ± 9.0 0.13 10.0 ± 0.6 0.05 8.7 ± 0.4 0.21 
> 20 years 55.5 ± 9.8 0.20 9.6 ± 0.7 0.05 8.6 ± 0.4 0.07 
Dose (packs per day) 
      
Never 56.6 ± 10.2 REF 9.4 ± 0.7 REF 8.5 ± 0.4 REF 
<1/2 58.5 ± 9.7 0.35 9.8 ± 0.6 0.13 8.7 ± 0.4 0.14 
1/2 – 1 53.0 ± 9.7 0.03 9.6 ± 0.7 0.08 8.5 ± 0.4 0.18 
>1 56.6 ± 10.2 0.47 9.5 ± 0.6 0.08 8.5 ± 0.3 0.08 
Time since smoking (years) 
      
Never 56.5 ± 10.3 REF 9.4 ± 0.7 REF 8.5 ± 0.7 REF 
< 5 years 60.2 ± 9.2 0.13 9.9 ± 0.7 0.01 8.9 ± 0.7 0.01 
5-10 years 60.4 ± 10.5 0.14 10.2 ± 0.8 0.09 8.8 ± 0.8 0.22 
11-20 years 55.5 ± 9.3 0.41 9.4 ± 0.7 0.51 8.3 ± 0.7 0.98 
> 20 years 51.9 ± 7.9 0.32 9.0 ± 0.6 0.74 8.1 ± 0.6 0.84 
Note. Among all cases. Estimated means and standard deviations were derived from linear regression models, 
adjusted for age, race, and Nanostring code set (where applicable). P-values are presented for the respective 
linear regression parameter estimates where ‘Never’ smokers serve as referent group. 
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Table 4.3. Estimated biomarker expression values for the effect of categorical smoking 
measures.  
 ER  
(WT%) 
ESR1 mRNA 
(Log2) 
Luminal Score 
(Log2) 
Metric Mean ± SD p Mean ± SD p Mean ± SD p 
Smoking 
      
Never 67.3 ± 5.7 REF 10.1 ± 0.5 REF 8.9 ± 0.2 REF 
Ever 64.5 ± 5.4 0.16 10.3 ± 0.5 0.03 9.0 ± 0.2 0.27 
Smoking status 
      
Never 68.5 ± 5.7 REF 10.1 ± 0.5 REF 8.9 ± 0.2 REF 
Former 65.2 ± 5.4 0.50 10.1 ± 0.5 0.27 8.9 ± 0.2 0.73 
Current 66.2 ± 4.6 0.09 10.5 ± 0.4 0.01 9.1 ± 0.2 0.13 
Duration (years) 
      
Never 68.6 ± 5.9 REF 10.1 ± 0.5 REF 8.9 ± 0.2 REF 
≤10 years 67.1 ± 5.5 0.38 10.3 ± 0.5 0.40 9.0 ± 0.2 0.82 
11-20 years 68.1 ± 5.4 0.87 10.5 ± 0.5 0.12 9.0 ± 0.2 0.44 
> 20 years 63.6 ± 5.1 0.10 10.2 ± 0.5 0.05 9.0 ± 0.2 0.23 
Dose (packs per day) 
      
Never 68.5 ± 5.7 REF 10.1 ± 0.5 REF 8.9 ± 0.2 REF 
<1/2 65.6 ± 5.2 0.09 10.3 ± 0.5 0.16 8.9 ± 0.2 0.77 
1/2 – 1 66.0 ± 5.4 0.59 10.1 ± 0.5 0.36 8.9 ± 0.2 0.67 
>1 64.8 ± 5.1 0.49 10.5 ± 0.4 0.01 9.1 ± 0.2 0.04 
Time since smoking (years) 
      
Never 68.4 ± 5.7 REF 10.1 ± 0.5 REF 9.0 ± 0.2 REF 
< 5 years 66.4 ± 4.9 0.33 10.5 ± 0.5 0.01 9.1 ± 0.2 0.04 
5-10 years 69.5 ± 6.0 0.96 10.4 ± 0.6 0.72 8.9 ± 0.3 0.92 
11-20 years 66.5 ± 5.5 0.70 10.2 ± 0.5 0.53 8.9 ± 0.2 0.96 
> 20 years 61.8 ± 4.1 0.09 9.8 ± 0.4 0.79 8.8 ± 0.2 0.59 
Note. Restricted to ER+ breast cancer cases. Estimated means and standard deviations were derived from linear 
regression models, adjusted for age, race, and Nanostring code set (where applicable). P-values are presented 
for the respective linear regression parameter estimates where ‘Never’ smokers serve as referent group. 
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                   A. Among All Cases                                                                  B. Among ER+ Cases  
 
Figure 4.4. Distribution of ER protein by never, former, or current smoking status. 
Note. Boxplots displaying the distribution of weighted percent ER (WT%) overall (A) and among ER+ breast tumors (B). ER 
WT% values were estimated from a linear regression model adjusted for age and race.  
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                       A. Among All Cases                                                                    B. Among ER+ Cases 
 
Figure 4.5. Distribution of ESR1 mRNA by never, former, or current smoking status. 
Note. Boxplots displaying the distribution of ESR1 overall (A) and among ER+ breast tumors (B). ESR1 values were estimated 
from a linear regression model adjusted for age, race, and Nanostring code set. * = p < 0.05, where ‘Never’ smokers serve as the 
referent group.  
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                       A. Among All Cases                                                                  B. Among ER+ Cases 
 
Figure 4.6. Distribution of the luminal score by never, former, or current smoking status. 
Note. Boxplots displaying the distribution of the luminal score (LS) overall (A) and among ER+ breast tumors (B). LS values 
were estimated from a linear regression model adjusted for age, race, and Nanostring code set. * = p < 0.05, where ‘Never’ 
smokers serve as the referent group.  
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CHAPTER 5: SMOKING, P53, EGFR, AND RELATED BIOMARKERS 
5.1 Background 
Although growing evidence suggests smoking as a possible risk factor for breast 
cancer, the mechanistic events leading to disease have not been clearly defined71. P53 – the 
most frequently mutated gene in breast cancer80 – functions as a tumor suppressor and its 
mutation or overexpression in breast tissue may serve as an etiologic marker for DNA 
damage from smoking. Indeed, results from the Carolina Breast Cancer Study demonstrated 
that breast cancer patients who were self-reported smokers at time of diagnosis had a higher 
prevalence of specific p53 mutations, when compared with their non-smoking counterparts 
(Conway et al.)57. In addition to gene sequencing technologies, researchers have also 
employed immunohistochemical (IHC) staining to detect p53 protein expression in breast 
tumors. However, the few studies that have examined smoking in relation to p53 IHC 
subtypes have yielded mixed results58,59. Elevated nuclear staining of p53 positively 
correlates to the presence of missense mutations, which stabilize the p53 protein, and may 
not adequately capture other genetic changes that could influence protein expression (e.g., 
deletion, frameshift)81.  Thus, single and multigene RNA measures that reflect biologic 
activity of p53 function in breast tissues may provide improved resolution in studies of 
smoking and breast cancer etiology65.  
While the DNA damaging effects of cigarette smoke are hypothesized to elicit 
disease82,83, it is plausible that other chemicals unrelated to mechanisms of DNA damage 
contribute to breast cancer initiation or progression. Nicotine, though not considered to be a 
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carcinogen, has been implicated in the development of breast cancer in animal and tissue 
culture studies27,29,84,85. Mouse xenograft models have demonstrated the transformation of 
normal mammary cells to neoplastic cells upon exposure to nicotine derivatives27. And 
similar to findings from lung cancer studies28, breast epithelial cells treated with nicotine 
show increased rates of cell proliferation through activation of EGFR29, providing a 
measurable clinical endpoint for the hypothesis that nicotine may be associated breast cancer 
phenotypes (i.e., EGFR+ breast cancer). Further, if smoking is associated with differential 
proliferative activity in breast tumors, a measure of cell proliferation may also serve as a 
suitable outcome to examine potential associations with smoking exposure.  Thus, examining 
smoking exposure in relation to EGFR expression and measures of cell proliferation may 
highlight mechanisms for these putative markers of smoking exposure in breast tissue. 
Finally, several studies have linked smoking to the ER+ breast cancer subtype, which 
represents a distinct etiologic class of disease characterized by overexpression of the 
estrogen-receptor7. Thus, a proper evaluation of proposed markers should be examined in 
light of established ER+ and ER- etiologic types. 
  In this study, we sought to evaluate smoking and its association with binary and 
continuous measures for p53 and EGFR gene expression, overall and stratified on ER+ or 
ER- breast cancer subtypes. We incorporated immunohistochemical data and RNA-based 
multigene signatures as measures of p53 and cell proliferation signaling patterns in tumors.  
5.2 Methods 
5.2.1 Study Population 
Phase III of the Carolina Breast Cancer Study (CBCS III) is a population-based case-
only study that combines epidemiology and molecular biology to examine environmental and 
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genetic risk factors for molecular subtypes of breast cancer. To be eligible for inclusion, 
patients must have been female and received a first and primary diagnosis of breast cancer 
between May 1, 2008 and October 31, 2013. The patient also must have resided in the 44-
county study region and been between the ages of 20 and 74 at the time of diagnosis. To 
examine potential risk factor differences by age and race, the CBCS employed a randomized 
recruitment strategy that was designed to oversample young and African American women73.  
Breast cancer cases were identified by a rapid case ascertainment system, 
implemented through collaboration between Lineberger Comprehensive Cancer Center 
(LCCC) and the North Carolina Central Cancer Registry (NCCCR). Briefly, CBCS contacted 
the patient’s primary physician to obtain permission to invite the patient into the study, 
yielding an overall response rate of 70% and a total of 2,998 women. Study participants were 
asked to consent to a nurse-administered in-person interview that took place in the study 
participant’s home or another pre-arranged location. The average time between study 
enrollment and interview was 6 months. The nurse administered questionnaire included items 
on family and personal medical history, reproductive history, smoking, alcohol, diet, 
medication use and occupational history. Upon consent, the nurse also collected a blood 
sample and objective anthropometric measurements of height (m), weight (kg, waist (m), and 
hip (m) circumference.  
5.2.2 Outcome Assessment 
The CBCS includes protein and RNA expression data on genes involved in estrogen-
signaling. At the time of interview, investigators asked study participants for permission to 
obtain formalin-fixed, paraffin-embedded (FPPE) tumor blocks or tissue slides from the 
hospital where the diagnostic surgery was to be performed. Tumor blocks were used to 
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construct tissue microarrays (TMAs) for IHC staining, where each patient’s tumor was 
represented by 1 to 8 cores on the microarray. RNA was extracted from the same tumor 
specimens used to construct the TMAs, using the Qiagen RNeasy FFPE kit and protocol. 
CBCS includes data for 1970 women included in the IHC analysis and 993 women included 
in both the IHC and RNA analyses. 
 ER, p53, and EGFR Protein Quantification. Automated quantification of ER, p53, 
and EGFR protein was determined by a Genie classifier and Aperio algorithms specified for 
nuclear or membrane proteins (Aperio Technologies, Vista, CA)61. We calculated percent 
positivity for each marker as the product of positively stained tumor cells for each core, 
multiplied by its core-specific weight, summed across all cores per patient. We assigned a 
binary cut point of ≥ 10% for ER positive, p53 positive, and EGFR positive tumors. 
Specifically, and with respect to protein expression cut points, ER positive and ER negative 
tumors are referred to as ER+ and ER-; p53 positive and p53 negative tumors are referred to 
as p53 IHC+ and p53 IHC- and, finally, EGFR positive and EGFR negative tumors are 
referred to as EGFR+ and EGFR-. 
MDM2 and EGFR mRNA Quantification. MDM2 (a negative regulator of p53) and 
EGFR were quantified using Nanostring technology. Briefly, total mRNA counts were 
assayed using target-specific molecular probes, which hybridize to RNA fragments in 
solution. Hybrids were then counted using microscopic imaging, yielding raw mRNA counts. 
Quality control and data normalization were performed using the NanostringNorm R 
package74. Data were first normalized to the geometric means of 6 internal positive controls 
and subsequently to the geometric means of 5 reference genes. Normalized mRNA counts 
were log2 transformed. MDM2 and EGFR were assayed along with other genes included in 1 
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of 3 Nanostring batches or code sets. Thus, all Nanostring analyses were adjusted for ‘code 
set’ to minimize potential batch effects. We assessed potential binary cut points for mRNA 
measures of MDM2 and EGFR using an expectation-maximization algorithm that is used to 
classify mixed Gaussian distributions75.  However, results from this analysis suggested that 
the distribution of values for each biomarker followed a single normal distribution and were 
not suitable for dichotomization (Figure 6.5 and Figure 6.6). Thus, we considered only 
continuous measures for MDM2 and EGFR mRNA. 
P53 mRNA Signature. We used the 48-gene signature identified by Troester et al. to 
classify breast tumors as p53 wildtype or p53 mutant65. The 48-gene predictor was applied to 
each case and classified based upon highest Pearson correlation with a centroid defined for 
either subtype. The mutant or wildtype designations characterize downstream biologic 
activity following p53 loss or activation, respectively. The p53 signature captures changes in 
p53-dependent gene expression due to both missense and non-missense mutations and other 
defects in regulators of p53. For all logistic regression analyses that examine associations 
between smoking and binary classifications for the p53 mRNA signature, p53 mutant tumors 
are referred to as ‘p53 Mut’ and p53 wildtype tumors are referred to as ‘p53 Wt’. mRNA 
transcripts used to define the p53 signature were quantified using Nanostring technology.  
Proliferation mRNA Signature. The PAM50 proliferation signature includes 11 highly 
correlated genes associated with cell proliferation in breast tumors64,72. The 11 genes include: 
BIRC5, CCNB1, CDC20, NUF2, CEP55, NDC80, MKI67, PTTG1, RRM2, TYMS, AND 
UBE2C. A description of the proliferation signature is described in Nielsen (2010)72. Briefly, 
each tumor is assigned a continuous score based on an algorithm that incorporates the 
average of expression levels for the 11 genes in the proliferation signature and linear 
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regression coefficients for clinical variable including breast cancer intrinsic subtype and 
tumor size. Tumors are classified as having high, medium, or low proliferation. For all 
logistic regression analyses that examine associations between smoking and binary 
classifications for the proliferation score (PS), tumors classified as high are referred to as ‘PS 
positive or PS+’; and tumors that are classified as medium or low are referred to as ‘PS 
negative or PS-’. Single mRNA transcripts included in the proliferation signature were 
quantified using Nanostring technology. 
5.2.3 Exposure Assessment 
History of smoking exposure was obtained during the nurse-administered in-person 
interview and includes data on smoking duration, frequency, and dose. Self-reported smoking 
is considered a valid measure of smoking exposure, with increased accuracy obtained during 
in-person interview formats66. Women in CBCS were considered ever smokers if they 
smoked at least 100 cigarettes during their lifetimes. CBCS investigators collected data on 
smoking history defined as ‘ever’ or ‘never’ (history); smoking status defined as ‘current’, 
‘former’, or ‘never’ (status); age at smoking initiation measured in years (initiation); smoking 
duration measured as the total number of years of smoking between initiation and current use 
or cessation (duration); number of cigarettes smoked per day (dose); and age at smoking 
cessation, where applicable.  
5.2.4 Data Analysis 
For each binary breast cancer classification, we used generalized logit models to 
estimate odds ratios (ORs) and 95% confidence intervals (CIs) for categorical measures of 
smoking and the p53 and EGFR-defined subtypes. We used linear regression to model the 
relationship between continuous measures of single or multigene markers and categorical 
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measures of smoking, adjusted for age, race, and Nanostring code set (where applicable). We 
calculated the estimated value of continuous biomarker expression for each individual, based 
on coding of the smoking exposure and covariate pattern, adjusted for age, race, and 
Nanostring code set. Expression levels for each biomarker were described according to 
interquartile range and visualized using box plots within categories of smoking. 
All analyses were conducted using SAS 9.4 (SAS Institute Inc, Cary, NC) and R 
version 3.3.3.  
5.3 Results 
Our analysis includes data on 1,970 women diagnosed with invasive breast cancer. 
Each patient had immunohistochemical data for tumor protein expression of ER, p53, and 
EGFR. In a subset of our study population (n=993) we measured mRNA levels of single 
gene (i.e., MDM2 and EGFR) and multigene markers (i.e., p53 signature and proliferation 
signature) that reflect signaling pathways of interest. Baseline patient characteristics were not 
substantially different between the two analytic groups (Table 5.1).  
5.3.1 Quantitative P53 Protein and MDM2 mRNA Expression  
Average p53 protein expression levels were slightly higher among p53 mutant (Mut) 
tumors (mean (SD), 7.3% (10.9)) compared to p53 wildtype (Wt) tumors [mean (SD), 3.9% 
(6.2)], where “Mut” and “Wt” signify tumors classified per the 48-gene signature by Troester 
et al65 (Figure 5.1). p53 wildtype tumors generally had low p53 protein expression levels, with 
80% having values below ten percent (i.e., proportion of tumor cells that stained positive for 
the p53 antigen). We also assessed expression levels for MDM2 – a negative regulator of 
p5386. P53 protein and MDM2 mRNA expression were not strongly correlated, but had a 
slight inverse association (r=-0.18, p < 0.0001). The density graph for MDM2 mRNA 
  
77 
expression values stratified by p53 mutant and wildtype mRNA binary classifications had 
substantial overlap, thereby suggesting the existence of a unimodal distribution (Figure 5.2). 
5.3.2 Smoking and P53 Protein Binary Subtypes  
Considering all patients regardless of ER status, we observed no apparent association 
between smoking and p53 IHC mutant and wildtype tumors (Table 5.2). However, when 
stratified by ER status, women with a history of smoking who were diagnosed with ER- 
breast tumors were more likely to also be classified as p53 IHC+ (i.e., ER-/p53 IHC+). 
Among ER- cases, current and former smokers had increased odds of p53 IHC+ tumors 
[Current: OR = 1.34 95% CI (0.77, 2.34); Former: OR = 1.49 95% CI (0.91, 2.44)]. In 
addition, women who smoked 20 or more years had greater odds of ER-/p53 IHC+ tumors 
when compared to their ER- counterparts with no history of smoking (OR = 1.86 95% CI 
(1.06, 3.27)).  
5.3.3 Smoking and P53 mRNA Binary Subtypes 
Although we observed evidence of associations between smoking and ER/p53 IHC 
defined subtypes (i.e., ER-/p53 IHC+), breast tumors classified as Wildtype (Wt) or Mutant 
(Mut) per the p53 RNA signature were not differentially linked to smoking exposure overall 
or within ER subtype (Table 5.3). Notably, when stratified by ER status, our RNA-based 
analyses were restricted to smaller sample sizes, thereby yielding less precise estimates.       
5.3.4 Smoking, Quantitative p53 Protein and MDM2 mRNA Expression 
We assessed quantitative levels of p53 protein and MDM2 mRNA expression in 
relation to ER subtype and smoking status at time of diagnosis using linear regression models 
(Figure 5.3). ER- breast cancer cases who were former smokers at time of diagnosis had 
higher p53 protein expression when compared to their never smoker counterparts [mean (%) 
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= 23.1 vs 18.1, p < 0.05]. However, we did not observe a complementary trend for MDM2 
mRNA expression when comparing former and never smokers [mean (log2) = 9.3 vs 9.3, p 
=0.81]. Similarly, considering duration >20 years, we observed statistically significant higher 
p53 protein levels but no trend for MDM2 mRNA expression (data not shown).  
5.3.5 Smoking and EGFR Protein Binary Subtypes 
In general, we did not observe a consistent association between smoking and binary 
subtypes for EGFR protein overall or when stratified by ER status (Table 3). However, there 
was a slight suggestion of an association between smoking dose and EGFR positivity. The 
highest category for smoking dose was associated with decreased odds of the EGFR+ 
subtype among women with ER+ tumors (OR = 0.67 95% CI (0.46, 0.97)) and increased 
odds of the EGFR+ subtype among ER- tumors (OR = 1.79 95% CI (0.99, 1.04)).  
5.3.6 Smoking and Quantitative EGFR protein and EGFR mRNA 
In addition, we did not observe an association between smoking and quantitative 
EGFR protein expression overall or within ER-defined subtypes (Figure 5.7). However, 
quantitative levels of EGFR mRNA were lowest among ER- cases who were former smokers 
compared to never smokers [mean (%) = 8.0 vs 8.4, p < 0.05].  (Figure 5.8).  
5.3.7 Smoking and Proliferation Binary Subtypes 
Smoking was consistently linked to decreased odds of having a PS+ breast tumor 
irrespective of ER status (Table 5.5). Specifically, measures for current smoking (OR = 0.67 
95% CI (0.47, 0.94)), smoking duration > 20 years (OR = 0.70 95% CI (0.49, 0.99)), and 
smoking cessation within 5 to 10 years of diagnosis (OR = 0.51 95% CI (0.28, 0.94)) had 
substantially lower odds of harboring the PS+ phenotype. In general, we observed similar 
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trends for analyses stratified by ER subtype. However, the ER-specific analyses yielded less 
precise estimates and were not statistically significant. 
5.4 Discussion 
In this study, we examined multigene signatures for p53, proliferation, and single-
gene EGFR as potential biomarkers of smoking exposure that serve as surrogate markers for 
DNA damage or growth factor dependent mechanisms. For p53 and EGFR, we observed null 
associations for smoking exposure when considering all cases. However, when stratifying on 
ER status, we observed temporal and dose-dependent associations between smoking and 
p53+ and EGFR+ molecular phenotypes among ER- cases, particularly for smoking duration 
> 20 years and those who smoked more than 1 pack of cigarettes per day. In addition, binary 
classifications for our multigene proliferation score was differentially linked to smoking 
exposure where current smoking, long smoking duration, and smoking cessation within 
specific time-windows were linked to decreased odds of the PS+ phenotype. 
Cigarette smoke contains more than 70 carcinogens that have been evaluated by the 
International Agency for Research on Cancer (IARC), and which comprise eight chemical 
classes 20. Two of the largest classes – the polycyclic aromatic hydrocarbons (PAHs) and the 
N-nitrosamines – are thought to be responsible for cancer initiation in lung tumors through 
development of DNA-adducts.21. Historically, investigators have proposed that PAHs store in 
breast adipose tissue to form PAH-DNA adducts; the resultant adducts are believed to lead to 
somatic mutations and subsequent tumor initiation82,87,88. P53 mutation has been evaluated as 
a probable marker of DNA damage in breast tissue following cigarette smoke exposure in 
several studies; however, results have been inconclusive. Conway et al. demonstrated that 
current smokers at the time of diagnosis had a higher prevalence of any p53 mutation in 
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exons 4-8, the DNA-binding region of the gene, when compared to former and never 
smokers57. However, in a similar analysis from the Long Island Breast Cancer Study Project 
(LIBCSP), Mordukhovich et al. reported null associations for current smoking and p53 gene 
mutation in the same exonic region60. 
In the present study, we used immunohistochemical staining to examine smoking in 
relation to p53 overexpression in breast tumors. Consistent with earlier reports from phases I 
and II of Carolina Breast Cancer Study, we found null associations between smoking and 
p53-expression (i.e., dark nuclear staining in 10% or greater of examined tumor cells)58. 
However, we note that the same analytic subset demonstrated associations between smoking 
and p53 genetic mutations in a separate analysis57. Furthermore, in a case-case analysis from 
the LIBCSP, Gammon et al. reported that smokers were twice as likely to be diagnosed with 
p53 IHC+ breast cancer when compared to never smokers, where p53 IHC+ was defined as 
moderate to strong staining in 10% or greater of tumor cells. The discordant results across 
studies may be explained by several factors including differences in assay protocol, selection 
of the p53 IHC cut point, and differences among the study populations.  
In addition, neither CBCS nor LIBCSP evaluated smoking and p53 IHC+ cut points 
in relation to ER expression, whose dichotomization defines two distinct classes of breast 
tumors. In the present study, though we observed no association between smoking and p53-
IHC breast cancer subtypes in breast cancer overall, temporal and dose-dependent patterns 
were observed among ER- cases. Among ER- cases, smoking duration of 20 years or more 
was associated with increased odds of the p53+ phenotype and higher levels of p53 protein 
expression. Interestingly, we also observed higher odds of the p53+ phenotype and higher 
quantitative levels of p53 protein among former smokers, but not current smokers. Thus, the 
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observed associations may reflect distal events in a woman’s smoking history such that 
smoking at diagnosis has limited influence on modulation of p53 expression at diagnosis. 
Further, observed association may be sensitive to the distribution of the ER+ and ER- tumors 
in a given study population. 
We did not observe similar associations between smoking and p53-mRNA binary 
subtypes. While the RNA signature captures downstream biological activity following p53 
loss, overexpression of p53 protein most commonly reflects missense mutations that lead to 
accumulation of the protein in cells. Thus, the effect of smoking in breast tissue may be 
specific to p53 point mutations as hypothesized by research that highlighted the increased 
presence of DNA adducts in breast tissues of smokers. For our present analysis and similar 
future analyses, p53 protein may serve as a preferred proxy for smoking-related DNA-
damage. 
We also examined EGFR as a potential marker of growth-factor mediated activity in 
the relationship between smoking and breast carcinogenesis. Until recently, nicotine - the 
most abundant and pharmacologically active component of cigarette smoke - has not been 
implicated in the development of breast cancer, though early studies demonstrated 
measurable levels of nicotine in the breast fluid of smokers23,24. However, in vitro studies of 
nicotine exposure to breast epithelium has been linked to increased rates of cell proliferation, 
migration, and overexpression of EGFR, providing insight to a possible biological 
mechanism for the increased risk of breast cancer among smokers; in vitro studies of breast 
epithelial cells exposed to nicotine have also demonstrated higher expression of EGFR 
compared with unexposed cells29,84,85,89 – and notably, it is linked to a poor clinical marker of 
disease. Similar to results for p53, when considering EGFR alone we observed no 
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differentiation of smoking exposure between EGFR+ and EGFR- subtypes. However, when 
stratified by ER status, we observed inverse associations between high smoking dose and the 
EGFR+ phenotype among ER- cases.  
Interestingly, smoking was linked to lower odds of the PS+ phenotype and, 
conversely, increased odds of the PS- phenotype. This observation suggests that smoking 
may be linked to lower proliferative activity in breast tumors. Though several in vitro studies 
have linked cigarette smoke – and nicotine exposure specifically -  to increased cell 
proliferation in breast tissue, studies have also demonstrated associations between smoking 
and lower rates of cell proliferation in other cell types and is thought to impede cell 
regeneration and wound healing90,91.  Further, we hypothesized that both EGFR and the cell 
proliferation signature could serve as biomarkers related to cell growth. Though we found no 
clear links between smoking and the EGFR subtypes, it may be reasonable to investigate 
EGFR as a mediator of cell proliferation in future analyses. 
Smoking has been linked to breast tumors that arise via genotoxic and growth-factor 
dependent mechanisms. In our study, we modeled those mechanisms as overexpression of 
single gene measures for P53 and EGFR, and differential expression of multigene signatures 
for p53 and cell proliferation. In addition, we also considered the expression of each marker 
by ER status Though we found no association between smoking and p53 or EGFR-defined 
subtypes independent of ER status, results from our study suggest that distal smoking 
exposure may be linked to differential expression of each among ER- cases. In addition, we 
observed consistently lower associations between smoking and the PS+ subtype, thereby 
suggesting that smoking may be linked to decreased proliferative activity. Future studies 
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should seek to replicate these findings in larger study samples and consider smoking in 
relation to additional biomarkers that may be related to DNA-damage or cell proliferation. 
5.5 Addendum 
When developing the analytic plan for Aim 2, we identified the possibility of 
evaluating smoking exposure in relation to the multigene proliferation score, though it was 
not described in our initial methodology plan.  This added analysis complements the 
hypothesis that smoking couple be linked to differential cell proliferation patterns in breast 
tumors.  
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Table 5.1. Age, race, and smoking characteristics of CBCS III study participants. 
  Overall   Nanostring Sampled 
        
Characteristics n %   n % 
Race           
AA 969 49.19   488 49.1 
Non-AA 1001 50.81   505 50.9 
Age           
<50 1039 52.74   506 51 
≥50 931 47.26   487 49 
Smoking History           
Never 1084 55.05   523 52.7 
Ever 885 44.95   469 47.3 
Missing 1     1   
Smoking Status           
Current 360 18.28   209 21.1 
Former 525 26.66   260 26.2 
Never 1084 55.05   523 52.7 
Missing 1     1   
Duration of smoking (active)           
Never 1084 55.08   523 52.7 
≤10 years 250 12.7   143 14.4 
11-20 years 208 10.57   98 9.88 
> 20 years 426 21.65   228 23 
Missing 2     1   
Amount smoked (active)           
Never 1084 55.05   523 52.7 
< 1/2 pack 344 17.47   184 18.5 
1/2-1 pack 353 17.93   187 18.9 
> 1 pack 188 9.55   98 9.88 
Missing 1     1   
Time Since Smoking           
Never 1084 55.05   523 52.7 
< 5 years 451 22.91   260 26.2 
5-10 years 67 3.4   31 3.13 
11-20 years 147 7.47   67 6.75 
> 20 years 220 11.17   111 11.2 
Missing 1     1   
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Figure 5.1. P53 protein expression (%), by p53 mRNA signature binary classification. 
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Figure 5.2. Density graphs for MDM2 mRNA expression (Log2), by p53 mRNA signature binary classification. 
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Table 5.2. Estimated odds ratios and 95% confidence intervals for p53 protein-defined 
breast cancer subtypes (adjusted for age and race). 
 Overall ER+ Cases ER- Cases 
 P53 IHC+  
vs. P53 IHC- 
P53 IHC+  
vs. P53 IHC- 
P53 IHC+  
vs. P53 IHC- 
    
Smoking history    
Ever 0.94 (0.72, 1.22) 0.84 (0.56, 1.28) 1.43 (0.95, 2.15) 
Smoking status    
Former 0.93 (0.68, 1.27) 0.73 (0.44, 1.21) 1.49 (0.91, 2.44) 
Current 0.95 (0.67, 1.34) 1.02 (0.60, 1.74) 1.34 (0.77, 2.34) 
Duration (years)    
< 10 1.02 (0.69, 1.52) 0.87 (0.46, 1.65) 1.78 (0.91, 3.47) 
11-20 0.64 (0.39, 1.00) 0.51 (0.23, 1.16) 0.75 (0.38, 1.48) 
> 20 1.07 (0.77, 1.48) 1.00 (0.61, 1.65) 1.86 (1.06, 3.27) 
Dose (packs/day)    
< 1/2 0.91 (0.64, 1.30) 0.65 (0.35, 1.20) 1.72 (0.98, 3.01) 
1/2 – 1 1.17 (0.83, 1.65) 1.20 (0.72, 1.99) 1.87 (1.02, 3.42) 
> 1 0.61 (0.36, 1.01) 0.61 (0.28, 1.33) 0.61 (0.29, 1.32) 
Time since exposure (years)    
< 5 0.91 (0.66, 1.25) 0.92 (0.55, 1.52) 1.34 (0.80, 2.22) 
5-10 0.59 (0.26, 1.35) 0.23 (0.03, 1.75) 0.83 (0.27, 2.49) 
11-20 1.10 (0.67, 1.80) 0.65 (0.27, 1.58) 1.80 (0.81, 3.99) 
> 20 1.02 (0.66, 1.58) 1.00 (0.53, 1.87) 1.81 (0.82, 4.00) 
Note. ER+ tumors are defined as tumors with ≥ 10 percent of examined tumor cells 
that stained positive for ER antigen; ER- tumors are defined as tumors with < 10 
percent staining of cells. Similarly, p53 IHC+ tumors are defined as tumors with ≥ 
10 percent of examined tumor cells that stained positive for p53 antigen; p53 IHC- 
tumors are defined as tumors with < 10 percent staining of cells. 
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Table 5.3. Estimated odds ratios and 95% confidence intervals for p53 Mut or Wt 
(mRNA) breast cancer subtypes (adjusted for age and race). 
 Overall ER+ Cases ER- Cases 
 Mut vs. Wt Mut vs. Wt Mut vs. Wt 
    
Smoking history    
Ever 1.11 (0.86, 1.45) 1.08 (0.75, 1.54) 0.79 (0.37, 1.66) 
Smoking status    
Former 1.11 (0.81, 1.53) 1.17 (0.74, 1.84) 1.07 (0.47, 2.43) 
Current 1.11 (0.80, 1.56) 0.99 (0.64, 1.54) 0.43 (0.12, 1.50) 
Duration (years)    
< 10 1.26 (0.86, 1.86) 1.10 (0.64, 1.87) 1.37 (0.52, 3.68) 
11-20 0.94 (0.60, 1.47) 1.02 (0.55, 1.88) 0.68 (0.19, 2.49) 
> 20 1.11 (0.80, 1.54) 1.09 (0.69, 1.72) 0.50 (0.16, 1.56) 
Dose (packs/day)    
< 1/2 1.15 (0.81, 1.63) 1.05 (0.65, 1.70) 1.07 (0.43, 2.69) 
1/2 – 1 1.13 (0.80, 1.61) 1.14 (0.70, 1.86) 0.47 (0.13, 1.67) 
> 1 1.01 (0.64, 1.60) 0.99 (0.52, 1.89) 0.81 (0.22, 3.00) 
Time since exposure (years)    
< 5 1.14 (0.73, 1.77) 1.07 (0.57, 2.02) 0.89 (0.24, 3.34) 
5-10 1.26 (0.74, 2.17) 1.80 (0.76, 4.24) 0.84 (0.18, 3.99) 
11-20 0.85 (0.40, 1.79) 0.67 (0.23, 1.94) 0.71 (0.08, 6.02) 
> 20 1.11 (0.81, 1.51) 1.02 (0.67, 1.55) 0.75 (0.30, 1.88) 
Note. ER+ tumors are defined as tumors with ≥ 10 percent of examined tumor cells 
that stained positive for ER antigen; ER- tumors are defined as tumors with < 10 
percent staining of cells. P53 mutant and wildtype designations are defined using a 
multigene RNA signature65. 
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             A. Among ER+ Cases                                                                B. Among ER- Cases 
 
Figure 5.3. Boxplots displaying the distribution of weighted percent p53 protein (%). 
Note. Boxplots for ER+ (A) and ER- (B) cases. p53(%) values were estimated from a linear regression model adjusted for age 
and race. Mean (SD): (A) Never [5.1 (0.03)], Former [4.5 (0.03)], Current [5.04 (0.03)]; (B) Never [18.1 (1.75)], Former [23.1 
(1.84)], Current [19.3 (1.74)].  
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                A. Among ER+ Cases                                                                B. Among ER- Cases 
 
Figure 5.4.  Boxplots displaying the distribution of MDM2 mRNA (log2)  
Note. Boxplots for ER+ (A) and ER- (B) cases. MDM2 values were estimated from a linear regression model adjusted for age, 
race, and Nanostring code set. Mean (SD): (A) Never [9.7 (0.2)], Former [9.5 (0.2)], Current [9.6 (0.2)]; (B) Never [9.0 (0.3)], 
Former [9.0 (0.2)], Current [9.0 (0.3)]. 
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Figure 5.5. Histogram of EGFR protein expression values among 1,964 breast tumors in CBCS III  
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Figure 5.6. Histogram of EGFR mRNA expression values among 1,011 breast tumors in CBCS III.
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Table 5.4. Estimated odds ratios and 95% confidence intervals for EGFR IHC-
defined breast cancer subtypes (adjusted for age and race). 
 Overall ER+ Cases ER- Cases 
 EGFR+ vs. 
EGFR- 
EGFR+ vs. 
EGFR- 
EGFR+ vs. 
EGFR- 
    
Smoking history    
Ever 0.95 (0.77, 1.16) 1.03 (0.82, 1.30) 1.14 (0.61, 2.11) 
Smoking status    
Former    
Current 0.99 (0.78, 1.26) 1.09 (0.83, 1.43) 1.20 (0.55, 2.60) 
Duration (years) 0.89 (0.68, 1.16) 0.96 (0.71, 1.29) 1.07 (0.48, 2.41) 
< 10    
11-20 1.17 (0.85, 1.62) 1.26 (0.88, 1.80) 1.54 (0.53, 4.51) 
> 20 0.95 (0.68, 1.33) 1.05 (0.72, 1.53) 1.18 (0.40, 3.49) 
Dose (packs/day) 0.84 (0.65, 1.08) 0.91 (0.69, 1.21) 0.93 (0.42, 2.06) 
< 1/2    
1/2 – 1 1.06 (0.80, 1.40) 1.21 (0.88, 1.67) 0.96 (0.44, 2.09) 
> 1 1.01 (0.77, 1.33) 1.13 (0.83, 1.54) 1.19 (0.48, 2.97) 
Time since exposure (years) 0.70 (0.50, 0.97) 0.67 (0.46, 0.97) 1.79 (0.99, 1.04) 
< 5    
5-10 0.88 (0.69, 1.12) 0.96 (0.73, 1.28) 0.89 (0.44, 1.79) 
11-20 1.06 (0.60, 1.89) 1.06 (0.57, 1.98) NE 
> 20 1.06 (0.71, 1.58) 1.32 (0.83, 2.09) 1.57 (0.36, 6.90) 
Note. ER+ tumors are defined as tumors with ≥ 10 percent of examined tumor cells 
that stained positive for ER antigen; ER- tumors are defined as tumors with < 10 
percent staining of cells. Similarly, EGFR+ tumors are defined as tumors with ≥ 10 
percent of examined tumor cells that stained positive for EGFR antigen; EGFR- 
tumors are defined as tumors with < 10 percent staining of cells. 
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             A. Among ER+ Cases                                                                B. Among ER- Cases 
 
 
Figure 5.7. Boxplots displaying the distribution of weighted percent EGFR protein (%)  
Note. Boxplots for ER+ (A) and ER- (B) cases. EGFR (%) values were estimated from a linear regression model adjusted for 
age and race. Mean (SD): (A) Never [22.9 (2.3)], Former [22.5 (2.4)], Current [22.5 (2.3)]; (B) Never [60.3 (1.9)], Former 
[59.5 (2.0)], Current [61.2 (1.8)].  
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             A. Among ER+ Cases                                                                B. Among ER- Cases 
 
Figure 5.8. Boxplots displaying the distribution of EGFR mRNA (log2)  
Note. Boxplots for ER+ (A) and ER- breast tumors (B). EGFR values were estimated from a linear regression model adjusted 
for age, race, and Nanostring code set. Mean (SD): (A) Never [7.2 (0.1)], Former [7.3 (0.1)], Current [7.2 (0.1)]; (B) Never 
[8.4 (0.4)], Former [8.0 (0.4)], Current [8.2 (0.3)].  
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Table 5.5. Estimated odds ratios and 95% confidence intervals for proliferation 
score breast cancer subtypes (adjusted for age and race). 
 Overall ER+ Cases ER- Cases 
 PS+ vs. PS- PS+ vs. PS- PS+ vs. PS- 
    
Smoking history    
Ever 0.69 (0.53, 0.90) 0.74 (0.50, 1.12) 0.70 (0.45, 1.11) 
Smoking status    
Former 0.71 (0.51, 0.99) 0.79 (0.48, 1.32) 0.59 (0.35, 1.02) 
Current 0.67 (0.47, 0.94) 0.70 (0.42, 1.17) 0.89 (0.48, 1.66) 
Duration (years)    
< 10 0.69 (0.46, 1.04) 0.83 (0.46, 1.50) 0.68 (0.34, 1.34) 
11-20 0.67 (0.42, 1.08) 0.66 (0.32, 1.37) 0.66 (0.31, 1.41) 
> 20 0.70 (0.49, 0.99) 0.73 (0.43, 1.23) 0.75 (0.41, 1.36) 
Dose (packs/day)    
< 1/2 0.71 (0.50, 1.02) 0.86 (0.51, 1.46) 0.65 (0.36, 1.18) 
1/2 – 1 0.66 (0.46, 0.96) 0.64 (0.36, 1.13) 0.82 (0.43, 1.57) 
> 1 0.69 (0.42, 1.14) 0.72 (0.33, 1.56) 0.64 (0.28, 1.43) 
Time since exposure (years)    
< 5 0.83 (0.52, 1.33) 1.12 (0.56, 2.22) 0.64 (0.29, 1.41) 
5-10 0.51 (0.28, 0.94) 0.30 (0.09, 1.01) 0.64 (0.25, 1.63) 
11-20 1.13 (0.53, 2.39) 1.43 (0.48, 4.31) 1.12 (0.28, 4.47) 
> 20 0.65 (0.47, 0.89) 0.69 (0.43, 1.12) 0.70 (0.41, 1.23) 
Note. ER+ tumors are defined as tumors with ≥ 10 percent of examined tumor cells 
that stained positive for ER antigen; ER- tumors are defined as tumors with < 10 
percent staining of cells. PS+ and PS- designations are defined using a multigene 
RNA signature72. 
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CHAPTER 6: DISCUSSION 
6.1 Summary 
In this dissertation, we examined relationships between smoking and breast tumor 
expression of protein and mRNA biomarkers that reflect biologic activity for estrogen-
mediated, genotoxic, and growth-factor dependent mechanisms of carcinogenesis. Using a 
case-only study design, we employed logistic and linear regression to evaluate binary and 
quantitative outcomes for biomarker expression. We used both single gene and multigene 
markers to characterize breast tumors, in efforts to explore associations between smoking and 
cross-sectional assessments of signaling pathways. Finally, we also incorporated latency 
functions to characterize protracted smoking exposure in our retrospective analysis to 
identify temporal associations between smoking and odds of binary breast cancer subtypes. 
6.2 Main Findings 
6.2.1 Smoking and estrogen-receptor expression in breast tumors 
Findings from our study lend support to the hypothesis that smoking may be linked to 
breast cancer via estrogen-mediated pathways. In our case-only study of nearly 2,000 
patients, we observed increased odds of the ER+ subtype for temporal and dose-dependent 
measures of smoking. We also demonstrated that these associations hold for ER-related 
subtypes characterized by ESR1 mRNA and a multigene luminal score (LS)72 that is 
comprised of expression values for eight genes involved in estrogen-signaling pathways. 
Notably, results from our study suggested that time of smoking exposure was an important
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 predictor of having a tumor that has high expression of genes involved in estrogen-signaling. 
Increased odds of ER+, ESR1+, and LS+ subtypes was most apparent among women who 
were self-reported current smokers at time of diagnosis. We also observed higher quantitative 
levels of ESR1 mRNA among current smokers, thereby suggesting that pre-diagnostic 
smoking proximal to date of diagnosis may modulate estrogen-receptor expression in breast 
tumors. Though we did not observe this same association with quantitative measures of 
protein, we suggest that mRNA may be a more sensitive measure of the biological activity 
for the estrogen-receptor.  
6.2.2 Smoking and biomarkers for p53, EGFR, and cell proliferation  
Though the literature on smoking and breast cancer risk is vast, few studies have 
assessed smoking in relation to specific biomarkers beyond ER. One longstanding hypothesis 
suggests that cigarette smoke may cause DNA-damage in breast tissue through the 
development of DNA adducts59,60. We selected overexpression of the p53 tumor suppressor 
gene as a marker of one DNA damage pathway. In addition, we evaluated EGFR, given a 
recent hypothesis implicating upregulated EGFR expression as biomarker linked to nicotine 
exposure in tissue culture models29. However, in our analysis we did not find evidence of 
links between smoking and protein measures for p53-defined or EGFR-defined breast cancer 
subtypes. Specifically, we observed no association between smoking measures and breast 
cancer subtypes defined by binary cut points for p53 and EGFR protein (i.e., p53 IHC+/p53 
IHC- and EGFR+/EGFR-), where p53 IHC+ and EGFR+ subtypes were defined as greater 
than or equal to ten percent of examined tumor cells.  
Guided by the literature and findings in Aim 1, we recognized ER as a biomarker 
whose dichotomization distinguished two distinct classes of breast tumors7,8. So, we 
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considered ER subtype when evaluating the association between smoking and our chosen 
biomarkers with proposed links to smoking and DNA-damage or growth factor-mediated 
mechanisms in breast tumors. When we stratified our analyses by ER status, we found the 
suggestion of a possible link between smoking and p53-positvity (p53 IHC+) among ER- 
cases. For EGFR, the stratified associations were less clear; differing metrics for smoking 
were linked to either increased or decreased odds of EGFR-positivity (EGFR+) among either 
ER+ or ER- cases. In addition, though we observed no association between smoking and 
quantitative measures for p53 protein or EGFR protein for breast cancer cases overall, 
differential expression of p53 protein was observed among former smokers, thereby 
enhancing the argument that past smoking history may be linked to differential expression of 
p53 protein in breast tumors.  
In addition to protein classifications for p53 and EGFR, we also considered single and 
multigene RNA measures that reflect biologic activity of p53, EGFR, and cell proliferation 
signaling pathways. We observed no clear patterns for associations between smoking 
measures and continuous measures for MDM2 (i.e., a negative regulator or p53) or EGFR 
mRNA expression. These observations suggest that smoking exposure captured at time of 
breast cancer diagnosis may not be related to modulation of these two biomarkers. In 
addition, our multigene RNA signature used to classify breast tumors as p53 “wildtype” or 
“mutant” was not linked to smoking exposure for breast cancer cases overall or when 
stratified by ER status. As discussed in chapter 5, the p53 RNA signature captures an array of 
mutational forms linked to defects in p53 regulation and may be too broad a measure for 
DNA-damage in our study if smoking is specifically linked to p53 missense mutations.  
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 During the conceptualization of this dissertation, we considered EGFR as a marker of 
a growth-factor mediated mechanism but found inconsistent links to smoking metrics. We 
later incorporated a cell proliferation signature to evaluate whether smoking was linked to 
differential proliferative activity. Interestingly, the multigene cell proliferation signature was 
consistently linked to decreased odds of the PS+ subtype for all smoking measures – thereby 
suggesting that smoking may be linked to lower cell proliferation rates in breast tumors. 
Though beyond the scope of the dissertation, future work may seek to evaluate whether 
EGFR gene expression mediates the relationship between smoking and the cell proliferation 
signature in breast tumors. 
6.3 Breast Tumor Biomarker Expression 
Evaluation of biomarkers in tumors can be performed via several methods including 
the use of high throughput technologies to quantify protein and mRNA. Though these 
methods allow advantages for large epidemiologic studies seeking to evaluate underlying 
mechanisms that link exposures to breast cancer risk, several measurement and classification 
issues emerge. These issues include: (1) classifying continuous variables into categorical or 
binary groups; (2) challenges with interpretation of biomarkers in relation to etiology vs. 
progression; (3) discordance between related biomarkers (i.e. protein vs. RNA); and (4) 
issues related to interpretation of single vs. multigene markers.   
6.3.1 Classifying continuous variables into categorical or binary groups 
Though we considered continuous gene expression, molecular biomarkers are 
routinely used in a dichotomous state – most notably estrogen-receptor (ER) protein. 
Contemporary clinical guidelines indicate an IHC cut point of 1% to define ER-positivity, 
though tumors with expression values between 1% and 9% are routinely considered as 
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borderline ER+ and those at 10% or higher as ER+62,92. The percentage of cells stained for 
ER follows a right-skewed distribution due to properties of the assay, which are tuned for 
high sensitivity to detect ER protein expression93. In our study, we used a threshold of 10 % 
typically define tumors as “strong” positives, yielding binary categories for ER that are 
suitable for epidemiologic investigations (Figure 6.1).  
Notably, our selection of 10% as a binary cut point for protein measures of p53 and 
EGFR mimics the 10% cut point used for ER protein expression. Although we explored use 
of a data-driven algorithm for establishing cut points75, we did not identify two or more 
distinct classes for either biomarker. Using the 10% cut point, we observed trends for p53 
and EGFR protein similar to that for ER, with right-skewed distributions characterized by a 
proportion of tumors with low biomarker expression and a uniform flat tail for higher 
expression values (Figure 6.2) (Figure 6.3). However, we acknowledge that more suitable cut 
points may exist for these two markers and that future work should seek to examine 
characteristics of IHC assays for p53 and EGFR quantification that may inform cut point 
identification. When utilizing established clinical biomarkers, dichotomization may rely on 
standard cut points, but when using other biomarkers, it is sometimes necessary to establish 
cut points.  Standards for these dichotomizations have not been developed.  Herein we 
present some approaches and rationale, but as genomic biomarkers become more widely 
utilized, standardized methods for categorization will be needed. Procedures may also differ 
for protein vs. mRNA cut points, as discussed in the following section. 
6.3.2 Discordance between related biomarkers 
With the inclusion of both protein and mRNA biomarker data, we were positioned to 
examine whether observed associations with smoking were consistent across marker types. 
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As previously discussed, smoking was associated with higher quantitative levels of ESR1 
mRNA, but not ER protein. We suggested that properties of the IHC assay may be attributed 
to this observed discordance, where sensitivity of the assay leads to saturated signals and 
reduced dynamic range for protein expression. It follows that binary cut points may be more 
appropriate for protein biomarkers in studies of etiology. Other molecular techniques such as 
those for RNA assessment may be more suitable for biomarker quantification.  
Nevertheless, we also sought to evaluate possible binary cut points for ESR1, MDM2, 
and EGFR mRNA to determine whether these markers performed similarly to their binary 
protein counterparts. The expectation-maximization algorithm – used to evaluate Gaussian 
mixture models – yielded two distinct populations of breast tumors for ESR1, but not MDM2 
or EGFR. When we considered the distribution of log-transformed values for ESR1 mRNA, 
we observed a bimodal distribution that suggests a mixture of 2 breast tumor populations 
(Figure 6.4). The distributions of MDM2 and EGFR mRNA were both normally distributed 
but unimodal, thereby suggesting single populations of expression values for these two 
markers (Figure 6.5) (Figure 6.6); thus, these markers were suitable for analyses that 
examined continuous gene expression, but there was no evidence of a reasonable binary cut 
point. Further, the identification of a binary cut point for ESR1 mRNA, which had high 
percent agreement with ER+ and ER- IHC cut points, highlights the unique nature of ER and 
its role in breast cancer characterization. 
6.3.3  Etiology vs. Progression 
Tumor biomarkers serve a variety of functions in both clinical and research settings.  
Given that tumor biomarkers may reflect etiologic effects or effects related to disease 
progression, it is often challenging to interpret their associations with proposed risk factors. 
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ER is a particularly complex marker as it may function as a prognostic, predictive, and 
etiologic marker. Overexpression of ER in breast tumors is generally regarded as signifying a 
less aggressive form of the disease, but has also been linked to higher rates of recurrence 
when compared to ER- tumors. It is also used to predict response to anti-estrogenic therapies 
and has demonstrated associations with distinct risk factor profiles for ER+ and ER- breast 
cancer subtypes13.  
Our previous work in the Carolina Breast Cancer Study demonstrated distinct 
associations between smoking and the ER+ subtype, which further suggests ER+ breast 
tumors comprise a distinct etiologic type. However, in the present study we observed that 
pre-diagnostic smoking close to time of diagnosis was linked to modulation of quantitative 
ESR1 mRNA expression levels in breast tumors and that smoking during this same time 
period was associated with the increased odds of being diagnosed with an ER+ or ESR1+ 
tumor. Thus, while smoking may be linked to specific etiologic subtypes defined by ER and 
it may also modulate ESR1 biomarker expression in existing tumors. It is unclear whether 
this quantitative variation in ER expression is related to etiology, progression, response to 
therapy, or some combination of these.  Future studies should aim to evaluate whether 
modulation of ER or ESR1 expression levels by smoking is linked to cancer progression 
events and cancer outcomes.    
When we evaluated p53 and EGFR as potential biomarkers of DNA-damage and 
growth factor mediated effects related to smoking exposure in breast tumors, we did not 
observe a consistent association between smoking and either biomarker. However, we also 
noted the importance of estrogen-receptor expression, which separates breast tumors into two 
distinct populations. Accordingly, we sought to examine the relationships between smoking 
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and p53 or EGFR gene expression separately for ER+ and ER- breast tumors. Though limited 
by sample size, we observed possible associations between smoking and p53 or EGFR 
biomarkers when we restricted our analyses by ER subtype. Thus, the influence of an 
exposure on a proposed marker of etiology or progression may function within breast cancer 
types defined by ER status. 
The various smoking metrics in our study allowed us to examine temporal associations 
to infer the most relevant time-windows for smoking and biomarker expression. We used 
logistic regression models with latency parameters to simultaneously model dose, duration, 
and time of exposure to demonstrate that the most relevant period for smoking and ER-
defined breast cancer may be during pre-diagnostic smoking exposure proximal to time of 
diagnosis. This finding may have clinical implications for molecular subtyping for breast 
cancer patients who are smokers at time of diagnosis, particularly for cases with borderline 
positivity. Future studies should seek to evaluate other proposed breast cancer risk factors in 
relation to estrogen-receptor expression to evaluate the extent to which exogenous exposures 
influence breast cancer intrinsic subtyping. In addition, we were limited by smaller sample 
size in our restricted analyses used to evaluate the relationship between smoking exposure 
and p53 and EGFR expression. Future studies within the Carolina Breast Cancer Study 
should seek to combine data from case-only and case-control data in order to bolster sample 
size.  
6.3.4 Single vs. Multigene Biomarkers 
In addition to single gene biomarkers, we selected three multigene signatures that 
reflect estrogen-mediated, DNA-damage response, and cell proliferation signaling pathways. 
These multigene signatures offer improved resolution over single gene markers may offer 
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advantages in capturing the biological pathway activity. However, one challenge with 
multigene signatures is that a variety of approaches are used for binary classifications of 
tumors. For example, the luminal score is the average expression of the 8 genes included in 
the signature, where each gene is given equal weight. The p53 signature uses nearest centroid 
and Spearman correlation to classify tumors as mutant or wildtype. And the proliferation 
score is the sum of the average of 11 genes, the regression coefficient of the tumor’s intrinsic 
subtype, and a measure of tumor size. Thus, our results may be somewhat sensitive to how 
the composite scores were devised; when there is no evidence of association for a particular 
measure, establishing true negative findings likely requires more thorough investigation of 
additional algorithms.  Likewise, it may be helpful to confirm that positive findings do not 
depend upon the specific algorithm and/or evaluating the stability of classification when 
using different algorithms. In addition, each signature yields a quantitative value that may be 
useful in regression analysis. Future research may consider how to incorporate such 
quantitative scores in analyses and how to interpret these.   
6.4 Conclusions 
The goal of this dissertation was to examine the association between smoking and 
breast tumors biomarkers linked to proposed mechanisms of carcinogenesis. We observed 
potential associations between smoking and each of the proposed mechanistic pathways, but 
also encountered several challenges related to interpretation of the data. The technical and 
conceptual issues discussed herein are important considerations for linking exposure to tumor 
biomarker expression and warrant further investigation to improve future studies that attempt 
to integrate epidemiologic and molecular biology in population-based studies of cancer 
etiology. In the era of genomic testing, it will be important to understand how past and 
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present exposures influence tumor biology to understand whether these exposures have 
implications for etiology, progression, or both. Smoking, specifically, may influence both the 
etiology of cancer and – as shown in our study – may be linked to increased expression of 
ESR1 mRNA among women who are smokers at diagnosis. Future work should evaluate 
other exposures in relation to breast tumor biomarkers linked to proposed mechanisms of 
carcinogenesis.  
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Figure 6.1. Distribution of estrogen-receptor (ER) protein expression values, as measured by immunohistochemistry.  
Note. Values are calculated as percentage of cells that stained positive for ER. 
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Figure 6.2. Distribution of p53 protein expression values. 
Note. Values are calculated as percentage of cells that stained positive for p53. 
  
  
1
0
9
 
 
Figure 6.3. Distribution of epidermal growth factor receptor (EGFR) protein expression values.  
Note. Values are calculated as percentage of cells that stained positive for EGFR. 
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Figure 6.4. Distribution of ESR1 mRNA values (Log2).  
Note. The bimodal peaks represent two distinct populations of ESR1-defined tumors. 
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Figure 6.5. Distribution of MDM2 mRNA values (Log2).  
Note. The unimodal peak suggests a single population of tumors defined by MDM2. 
  
1
1
2
 
 
Figure 6.6. Distribution of EGFR mRNA values (Log2).  
Note. The unimodal peak suggests a single population of tumors defined by EGFR. 
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